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There are few studies describing colonisation with extended spectrum beta-lactamase-
producing Enterobacterales (ESBL-PE) and carbapenem-resistant Enterobacterales (CRE) 
among children in sub-Saharan Africa. Colonisation often precedes infection and multi-drug-
resistant Enterobacterales are important causes of invasive infection.  
Methods: 
In this prospective cross-sectional study, conducted between April and June 2017, 200 
children in a tertiary academic hospital were screened by rectal swab for EBSL-PE and CRE. 
The resistance-conferring genes were identified using polymerase chain reaction technology. 
Risk factors for colonisation were also evaluated. 
Results: 
Overall, 48% (96/200) of the children were colonised with at least one ESBL-PE, 8 of these 
with 2 ESBL-PE, and one with a CRE (0.5%, 1/200). Common colonising ESBL-PE were 
Klebsiella pneumoniae (62.5%, 65/104) and Escherichia coli (34.6%, 36/104). The most 
frequent ESBL-conferring gene was blaCTX-M in 95% (76/80) of the isolates. No resistance- 
conferring gene was identified in the CRE isolate (Enterobacter cloacae). Most of the 
Klebsiella pneumoniae isolates were susceptible to piperacillin/tazobactam (86.2%) and 
amikacin (63.9%). Similarly, 94.4% and 97.2% of the Escherichia coli isolates were 
susceptible to piperacillin/tazobactam and amikacin, respectively. Hospitalisation for more 
than 7 days before study enrolment was associated with ESBL-PE colonisation. 
Conclusion:
Approximately half of hospitalised children in this study were colonised with ESBL-PE. This 
highlights the need for improved infection prevention and control practices to limit the 
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CHAPTER 1: Introduction 
1.1 Context 
Infection with multidrug-resistant organisms (MDRO) is becoming a threat to global health 
[1, 2]. An estimated 700,000 individuals died from MDRO annually in 2014 with an 
estimated increase in healthcare costs of 20-35 billion dollars in the USA alone [3, 4]. If the 
current trajectory of infection with MDRO continues, global estimates are that 10 million 
individuals will die annually by 2050, higher than the combined deaths from cancer and road 
traffic accidents, and healthcare costs will have escalated to 10 trillion dollars between now 
and then [3]. Added to this, MDROs pose great challenges to advances in medicine, 
especially with the use of technology in novel therapies and organ transplantation. Notable 
among the MDROs are  extended spectrum beta-lactamase-producing Enterobacterales 
(ESBL-PE) and carbapenem-resistant Enterobacterales (CRE) [5]. They are among the 
pathogens categorised as critical in the World Health Organisation list of priority antibiotic-
resistant pathogens [5]. These organisms are notorious for causing healthcare-associated 
infection around the world, and there are growing concerns about their increasing 
contribution to community-acquired infections. Invasive infection with CRE is associated 
with high mortality, high cost of management, few therapeutic options and the absence of 
effective consensus treatment guidelines [6].  
The ESBL-PE, particularly Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. 
coli), possess genes which encode extended spectrum beta-lactamases (ESBLs) that 
hydrolyse the beta-lactam ring in most penicillins, cephalosporins including the 
oxyiminocephalosporins,  and monobactams [7, 8]. These enzymes have no activity against 
the cephamycins such as cefoxitin and cefotetan, and carbapenems, and are inhibited by beta-
lactam inhibitors such as clavulanic acid [8]. The genes that encode for these enzymes are 
carried on plasmids which often also carry genes conferring resistance to other antibiotics 
like the fluoroquinolones, aminoglycosides, tetracyclines, chloramphenicol, trimethoprim 
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and sulphonamides making ESBL-PE multidrug-resistant organisms.  The ESBLs belong to 
the Ambler class A enzymes. More than 200 have been identified. Initially, Temoneira 
(TEM) and sulfhydryl variable (SHV) enzymes were discovered. Over time the cefotaxime 
(CTX)-M-type (CTX-M), enzymes have become the most important ESBLs globally [9-14]. 
The CTX-M enzymes are found in both K. pneumoniae, which is responsible for most 
healthcare-associated infections, and E. coli which is responsible for many community- 
acquired ESBL infections [11-15]. 
Carbapenem-resistant Enterobacterales employ several resistance-conferring mechanisms 
including mobile genetic elements such as plasmids that encode carbapenemases. The 
carbapenemases hydrolyse the carbapenem ring more efficiently than other beta-lactamases. 
The carbapenemase-encoding genes on plasmids can be transferred from one bacterium to 
another, facilitating local transmission and global spread.  
There are few reports of ESBL-PE and CRE colonisation in children. Colonisation often 
precedes infection [16, 17]. Infection risk among children previously colonised with CRE 
have ranged from 3.4 to 28.2% [18-21]. Risk of colonised children progressing to infection 
is increased by existing metabolic disease, previous carbapenem use, neutropaenia and prior 
surgical procedures [20].  
Many of the hospital-based paediatric studies on ESBL-PE colonisation are in neonates, often 
in neonatal intensive care units (NICUs). Prevalence ranged from 4.3% to 75% [22-24]. 
Studies of ESBL-PE colonisation among hospitalised paediatric patients outside the neonatal 
age range have recorded prevalence between 18.5% and 57.1% [25-27], whereas carriage in 
community settings is lower, ranging from 0.1% to 12.4% [28-32]. In some settings, 
community carriage has increased over time. For example, surveillance studies in Bolivia 
and Peru over a decade show a steady rise from 0.1% in 2002 to 12.4% in 2011 [28, 32, 33]. 
Community carriage is thought to act as a reservoir for the development of community-
acquired ESBL infections, particularly E. coli infections. 
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Factors that predispose to ESBL-PE colonisation in the neonatal period include prior 
carbapenem, penicillin and aminoglycoside exposure, prolonged hospitalisation, early-onset 
pneumonia, prolonged antibiotic use, formula milk feeds and having an ESBL-PE colonised 
mother [22, 24, 34-38]. Risk factors for ESBL-PE colonisation in older children include 
mechanical ventilation, prolonged hospital stay, prior antibiotic use and prior hospitalisation 
[25, 26]. However, ESBL-producing E coli carriage documented among children in a very 
remote community in Senegal where prior antibiotic use was most unlikely suggests that 
other factors may play a role in promoting colonisation [29]. Conversely, breastfeeding 
confers protection against ESBL-PE colonisation in the new born period [37, 39]. In early 
studies, ESBL-PE colonisation was associated with the SHV enzyme. More recent studies 
suggest that the CTX-M enzyme now predominates. [9, 24, 35, 36, 39].  
Studies in children have reported CRE colonisation rates of 0.5% to 29.5% [18-21, 40-48]. 
All the studies on CRE colonisation have documented K. pneumoniae colonisation [18-21, 
43, 44] while two studies also documented Serratia species, E. coli and Enterobacter species 
colonisation [18, 21]. In Turkey, the predominant carbapenemases were New Delhi metallo-
beta-lactamase (NDM), oxacillinase (OXA) and imipenemase (IMP) [19, 21]. Klebsiella 
pneumoniae carbapenemase (KPC) and NDM are frequently isolated in the United Kingdom 
[18], while KPC was the predominant carbapenem resistance gene in Italy [43] and Verona 
Integron-Mediated Metallo-beta-lactamase (VIM) in Greece [44]. Risk factors associated 
with CRE colonisation include carbapenem exposure, transfer between healthcare facilities, 
aminoglycoside exposure, surgical procedures, urinary catheterisation, nasogastric intubation 
and prolonged antibiotic administration [19-21, 43].   
Despite the global spread of these organisms and the association of widespread and 
indiscriminate use of broad-spectrum antibiotics with their emergence, little is known about 
the epidemiology of ESBL-PE and CRE colonisation and infection on the African continent, 
especially in children. There have been reports of ESBL-PE infections in South Africa from 
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the early 1990s, but most reports are in adults [49]. One of the first reports in children 
described the treatment and outcome of a case series of invasive CRE infections [50]. To 
address the dearth of ESBL-PE and CRE colonisation research in children in Africa, the 
present study describes ESBL-PE and CRE colonisation including prevalence, factors 
associated with colonisation and the distribution of ESBL genes among ESBL-PE isolates. 
1.2 Ethical considerations 
The study was conducted in accordance with the Helsinki Declaration. The study protocol 
was approved by the Human Research Ethics Committee (HREC), Faculty of Health 
Sciences, University of Cape Town, reference number: HREC REF: 898/2016. The Research 
Committee at the Red Cross War Memorial Children’s Hospital (RCWMCH) also approved 
the study. 
Written informed consent was obtained in the preferred language (English, Afrikaans or 
isiXhosa) from the parents or legal guardian, and children aged 12 years and above before 
enrolment. Children aged between 7 years and above provided written informed assent before 
being enrolled into the study. The services of translators were employed where necessary 
during consenting, assenting and enrolment procedures. 
Study subjects and their parents or legal guardian were informed of their ESBL-PE and/or 
CRE colonisation status. When colonisation was documented, the implications for clinical 
care and infection control practices were explained to the study subjects and parents or legal 
guardians. The result was also provided to the attending physicians and other healthcare 
providers involved in their care. Parents or legal guardians of study subjects who had already 
been discharged from hospital at the time of receipt of the results were informed 
telephonically. 
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There are few studies describing colonisation with extended spectrum beta-lactamase-
producing Enterobacterales (ESBL-PE) and carbapenem-resistant Enterobacterales (CRE) 
among children in sub-Saharan Africa. Colonisation often precedes infection and multi-drug-
resistant Enterobacterales are important causes of invasive infection.  
Methods: 
In this prospective cross-sectional study, conducted between April and June 2017, 200 
children in a tertiary academic hospital were screened by rectal swab for EBSL-PE and CRE. 
The resistance-conferring genes were identified using polymerase chain reaction technology. 
Risk factors for colonisation were also evaluated. 
Results: 
Overall, 48% (96/200) of the children were colonised with at least one ESBL-PE, 8 of these 
with 2 ESBL-PE, and one with a CRE (0.5% (1/200)). Common colonising ESBL-PE were 
Klebsiella pneumoniae (62.5%, 65/104) and Escherichia coli (34.6%, 36/104). The most 
frequent ESBL-conferring gene was blaCTX-M in 95% (76/80) of the isolates. No resistance- 
conferring gene was identified in the CRE isolate (Enterobacter cloacae). Most of the 
Klebsiella pneumoniae isolates were susceptible to piperacillin/tazobactam (86.2%) and 
amikacin (63.9%). Similarly, 94.4% and 97.2% of the Escherichia coli isolates were 
susceptible to piperacillin/tazobactam and amikacin, respectively. Hospitalisation for more 
than 7 days before study enrolment was associated with ESBL-PE colonisation. 
Conclusion: 
Approximately half of the hospitalised children in this study were colonised with ESBL-PE. 
This highlights the need for improved infection prevention and control practices to limit the 
dissemination of these microorganisms. 
Key Words: Colonisation, ESBL, CRE, children, Africa 
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INTRODUCTION 
Infection with multidrug-resistant organisms is a threat to global health [1, 2]. Notable are 
the emergence of extended spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) 
and carbapenem-resistant Enterobacterales (CRE) [3]. They are among pathogens 
categorised as critical on the World Health Organization list of priority antibiotic resistant 
pathogens [3].  These organisms are notorious for causing healthcare-associated infections, 
and there are growing concerns about their increasing contribution to community-acquired 
infections [4]. Invasive infection with CRE is associated with high mortality, high cost of 
management, few therapeutic options and the absence of effective consensus treatment 
guidelines [5].  
Colonisation often precedes infection, however reports of ESBL-PE and CRE colonisation 
progressing to infection in children are rare [6, 7]. Most paediatric studies on ESBL-PE 
colonisation are in neonatal intensive care units (NICUs) with reported prevalence ranging 
from 4.3% to 75% [8-10]. Outside the neonatal age, ESBL-PE colonisation among 
hospitalised paediatric patients have recorded prevalence between 18.5% and 57.1% [11-13] 
while carriage in community settings is lower, ranging from 0.1% to 12.4% [14-18]. In some 
settings, community carriage has increased over time. For example, surveillance studies in 
Bolivia and Peru, over a decade, show a steady rise from 0.1% in 2002 to 12.4% in 2011 [14, 
18, 19]. Community carriage may be a reservoir for the development of community-acquired 
ESBL-PE infections, particularly Escherichia coli infections [4]. 
Factors which predispose to ESBL-PE colonisation in the neonatal period include prior 
carbapenem, penicillin and aminoglycoside exposure, prolonged hospitalisation, early onset 
pneumonia, prolonged antibiotic use, formula milk feeds, and having an ESBL-PE colonised 
mother [8, 9, 20-25]. Risk factors for ESBL-PE colonisation in older children include 
mechanical ventilation, prolonged hospital stay, prior antibiotic use and prior hospitalisation 
[11, 12]. However, ESBL-producing E. coli carriage documented among children in a very 
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remote community in Senegal, where prior antibiotic use was most unlikely, suggested that 
other factors may play a role in promoting colonisation [15]. Conversely, breastfeeding 
confers protection against ESBL-PE colonisation in the new born period [23, 26]. In early 
studies, ESBL-PE colonisation was associated with the sulphydryl variable (SHV) enzyme. 
More recent studies suggest that the cefotaxime-hydrolyzing beta-lactamase, (CTX-M) 
enzyme now predominates [4, 9, 21, 22, 26, 27].  
Studies in children have reported CRE colonisation rates of 0.5% to 29.5% [28-40]. All the 
studies on CRE colonisation have documented Klebsiella pneumoniae colonisation [31-33, 
35, 37, 40] while two studies also documented colonisation with Serratia spp., E. coli and 
Enterobacter spp. [31, 40]. Though there are likely due to geographical variations, one or 
more carbapenemases have been reported on all continents [31-33, 35, 40]. Risk factors 
associated with CRE colonisation include carbapenem exposure, transfer-in from other health 
facilities, aminoglycoside exposure, surgical procedures, urinary catheterisation, nasogastric 
intubation and prolonged antibiotic administration [32, 35, 37, 40]. Infection risk among 
children previously colonised with CRE have ranged from 3.4 to 28.2% [31, 35, 37, 40]. Risk 
of children colonised with carbapenem-resistant K. pneumoniae progressing to infection is 
increased by existing metabolic disease, previous carbapenem use, neutropaenia and prior 
surgical procedures [37]. 
Despite the global distribution of these organisms and the association of their emergence due 
to widespread and indiscriminate use of broad-spectrum antibiotics, little is known about the 
epidemiology of ESBL-PE and CRE colonisation and infection on the African continent, 
especially in children. There have been reports of ESBL-PE infections in South Africa from 
the early 1990s, and some more recent studies describing ESBL-PE infections, but few 
colonisation studies [41-44]. One of the first reports of CRE infection and colonisation in 
children in South Africa described the treatment and outcome of a case series of invasive 
CRE infections [45]. To address the dearth of ESBL-PE and CRE colonisation research in 
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children in Africa, we describe ESBL-PE and CRE colonisation at a children’s hospital 
including prevalence, factors associated with ESBL-PE colonisation, and the distribution of 
ESBL genes among ESBL-PE isolates. 
METHODS 
Study design and setting 
This prospective, cross-sectional study was conducted at Red Cross War Memorial 
Children’s Hospital (RCWMCH) in Cape Town, South Africa, a 273-bedded tertiary hospital 
affiliated to the University of Cape Town academic complex and dedicated to the care of 
children aged 13 years and below. The hospital is a referral centre for sick children from the 
Western Cape Province, but also receives referrals from surrounding provinces. 
Enrolment and sampling 
Recruitment took place in four wards at RCWMCH, including two general medical wards 
and two surgical wards. All children admitted to the four wards were eligible for enrolment, 
except those who experienced colonisation or infection with ESBL-PE and/or CRE in the 
previous 1-year period. 
A systematic sampling approach was employed for selecting study participants. From the 
daily ward list of children resident in the four wards, every third patient was approached for 
enrolment. If the inclusion criteria were not met, the next patient on the ward list was 
approached for enrolment. Enrolment took place from Monday to Friday. Between 3 and 8 
patients were enrolled on any one day. Enrolment alternated between the medical and surgical 
patients to ensure that each patient type constituted a minimum of 45% of all enrolled study 






Demographic and clinical information of the enrolled patients was entered on a study-specific 
structured data sheet. The information included age at enrolment, gender, source of admission 
– either from a health care facility or convalescence home, current diagnosis, surgical 
procedures, and intensive care unit (ICU) treatment in the current admission or the preceding 
12 months. Information on antibiotic use was also collected such as the type and duration of 
antibiotic therapy in the 12 months preceding this admission or in the current admission. 
Information on out-of-hospital antibiotic exposure was mainly as reported by caregiver 
recall, which was limited. While information on in-hospital antibiotics used was collected 
from the patient’s clinical records at RCWMCH, exposure(s) at other hospitals could not be 
ascertained and might have been missed.  
Stool specimen collection 
A soft tipped TransystemTM sterile transport swab (COPAN Italia S.a.A via Perotti 10, 
25125 Brescia Italy) was used to collect rectal stool specimens in a quiet, comfortable room. 
Swabbing was performed by an experienced research nurse assisted by a chaperone and 
usually in the presence of the child’s parent or legal guardian. All measures were taken to 
minimise patient discomfort. The specimens were transported to the National Health 
Laboratory Service (NHLS) medical microbiology laboratory, Groote Schuur Hospital 
(GSH), Cape Town, for processing within 6 hours of collection.  
Microbiological Procedures  
All microbiological procedures were performed at the medical microbiology laboratory, 
GSH, located 4.3 km from RCWMCH. Stool specimens were plated onto ChromID ESBL 
media (bioMérieux, Marcy l’Etoile, France) and incubated at 37°C for 24 hours. Suspected 
colonies were subcultured onto blood agar plates for pure growth. Purified isolates were 
identified using the Vitek 2® Gram negative card with susceptibility testing performed using 
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the AST GN-N255 card (bioMérieux, Marcy l’Etoile, France). Where necessary, this was 
supplemented with E-test (bioMérieux, Marcy l’Etoile, France) gradient diffusion to confirm 
minimal inhibitory concentrations (MICs) of ertapenem, imipenem and meropenem. MICs 
were interpreted according to the 2017 Clinical and Laboratory Standards Institute (CLSI) 
guidelines [46] while ESBLs and CRE were reported based on the Advanced Expert System 
(AES) interpretation of the Vitek 2® system. The susceptibility of Enterobacterales isolated 
was evaluated for the following antibiotics: ampicillin, co-amoxiclav, piperacillin-
tazobactam, cefuroxime, cefoxitin, ceftriaxone, ceftazidime, cefepime, ertapenem, 
meropenem, imipenem, ciprofloxacin, gentamicin, amikacin, cotrimoxazole, tigecycline and 
colistin.  All isolates were stored at -70°C on microbeads for further molecular testing for 
EBSL and carbapenemase-producing genes.   
Molecular testing for common ESBL and carbapenemase genes  
Stored isolates were grown overnight (18 - 24 hours) on McConkey agar plates, before sub-
culturing onto 2% Blood agar. A loop-full of each culture was suspended in 750 µl 
BashingBead™ Buffer and pre-lysed on the Tissue Lyser in a ZR BashingBead™ Lysis Tube 
(Zymo Research Corporation), at 50Hz for 5 min. The Lysis tube was centrifuged at 10 000 
rpm, and 200 µl of the supernatant extracted and purified using the QIAsymphony DSP 
Virus/Pathogen Kit (Qiagen), according to the manufacturer’s recommendations. 
Using gene-specific primers, selected commonly encountered ESBL and carbapenemase 
genes were detected and amplified by PCR reaction. The primers used are shown in 
Supplementary Table I and detailed methods are detailed in a recent publication [47]. The 
amplification products were analysed by agarose gel electrophoresis with 1.5%, and 
visualised with ethidium bromide and using ultraviolet light. Positive amplicons were 




HIV-exposed but uninfected child: A child <18 months old in whom a positive HIV 
serological test was documented in either the mother or the child, but the HIV DNA PCR test 
was negative in the child who was not on antiretroviral therapy (ART).  
HIV Infection: A positive HIV DNA PCR result confirmed by either a HIV RNA PCR or 
repeat HIV DNA PCR test in any child < 18 months old, or 2 positive serological test results 
(HIV ELISA or HIV Rapid test) or a positive HIV DNA PCR result confirmed by either a 
HIV RNA PCR or repeat HIV DNA PCR test in a child > 18 months old were considered 
HIV-infected [48].  
Extended Spectrum Beta-Lactamase Producing Enterobacterales (ESBL-PE): 
Enterobacterales were categorised as ESBL-PE according to the Vitek 2® Advanced Expert 
System (AES) interpretation of the AST GN-N255 card.  This categorisation is based solely 
on the pattern of susceptibility and resistance to different cephalosporins as the card lacks 
wells containing cephalosporins combined with a beta-lactamase inhibitor [49]. 
Carbapenem-resistant Enterobacterales (CRE): Enterobacterales which are resistant to 
any carbapenem antibiotic (minimum inhibitory concentration of ≥4 mcg/ml for doripenem, 
meropenem or imipenem, or ≥2 mcg/ml for ertapenem) according to 2017 CLSI breakpoints 
[46]. Resistance to carbapenems may result from several mechanisms including alteration of 
outer membrane permeability or the production of carbapenemases. Common carbapenemase 
genes include blaNDM, blaKPC, blaGES, blaVIM, blaOXA-48-like and blaIMP [46].  
Co-morbidity:  An underlying chronic medical condition for which the patient was receiving 
care at the time of enrolment.  
Major surgery: An invasive operative procedure in which extensive resection is performed, 
e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general,
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if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is 
considered major [50].  
Statistical analysis 
Data were entered in SPSS Statistics Version 24.0 Software (IBM, Armonk, New York, 
USA) and analysed. Descriptive statistics, for continuous variables, was reported as medians 
with interquartile ranges or, where applicable as means and standard deviations. Categorical 
variables were reported as proportions and percentages.  The 95% confidence interval (CI) 
for binomial proportions were estimated for mid-point prevalence estimates. Categorical 
variables were compared using either the uncorrected chi square test or Fisher’s exact test 
while continuous variables were analysed using the Student’s t test or analysis of variance 
(ANOVA). Non-normally distributed data were compared using Mann-Whitney U test. Two-
tail p values <0.05 were considered statistically significant. 
Univariate analyses were used to identify potential risk factors associated with rectal 
colonisation by ESBL-PE.  All factors with a p value <0.2 on univariate analysis, and those 
biologically plausible or reported in literature, were then analysed in a binomial logistic 
regression model to identify factors independently associated with ESBL-PE colonisation.  
The binomial logistic regression model was built using a stepwise backward selection. The 
univariate results were reported using unadjusted odds ratios (ORs) and 95% confidence 
interval (95% CI), and the logistic regression results expressed as adjusted odds ratios (aORs) 
and 95% CI.   
Ethical consideration 
The study was conducted in accordance with the Helsinki Declaration. The study protocol 
was approved by the Human Research Ethics Committee, Faculty of Health Sciences, 
University of Cape Town, reference number: HREC REF: 898/2016. The Research 
Committee at the RCWMCH also approved the study. 
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Written informed consent was obtained in the preferred language (English, Afrikaans or 
isiXhosa) from the parents or legal guardian, and children aged 12 years and above before 
enrolment. Children aged between 7 years and above provided written informed assent before 
being enrolled into the study. The services of translators were employed where necessary 
during consenting, assenting and enrolment procedures. 
Children and their legal guardian were informed of their ESBL-PE and/or CRE colonisation 
status. When colonisation was documented, the implications for care management, and 
infection control practices were explained. The result was also provided to the attending 
physicians and other health care providers involved in their care. Parents or legal guardian of 




Of a total of 299 children who were selected for enrolment, 99 were excluded for various 
reasons. Thus, a total of 200 children were enrolled and completed the study. Supplementary 
Fig. 1 depicts participant enrolment, phenotypic and genotypic results. 
Supplementary Fig 1. Flow chart depicting patient enrolment, phenotypic and 
genotypic testing results 
Prevalence of ESBL-PE and CRE colonisation 
Of 200 participants enrolled, 96 were colonized by at least one ESBL-PE, giving an ESBL-
PE colonisation prevalence of 48% (95% CI 40.9-55.2%). Of these, 8 patients were colonised 
by two different ESBL-PE, prevalence of 4% (95% CI 1.9-7.5%). One patient was colonised 
by a carbapenem-resistant Enterobacter cloacae (E. cloacae) giving a CRE colonisation 
prevalence of 0.5% (95% CI 0.02–2.4%). Of the total 104 ESBL-PE isolates collected from 
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the 96 ESBL-PE colonized participants, K. pneumoniae accounted for 62.5% (65/104), E. 
coli 34.6% (36/104), Klebsiella oxytoca (K. oxytoca) 1.9% (2/104), and E. cloacae 1.0% 
(1/104). 
Characteristics of participants 
Of the 200 enrolled children, 60.5% were male, the median age was 12 months (range 4 days 
– 7 years and 4 months), and 59.6% (119/200) were less than 24 months of age. The HIV 
status was known in 153 patients; 3.5% (7/200) were HIV-infected, 19.5% (39/200) were 
HIV-exposed but uninfected and 53.5% (107/200) were HIV-unexposed. Of the 47 children 
with unknown HIV status, 89.4% (42/47) were enrolled in the surgical wards. The most 
frequent primary diagnoses were pneumonia, bone and soft tissue infection and acute 
diarrhoeal disease (Table 1). There was no significant difference in the proportions of 
colonised and non-colonised children with pre-existing co-morbid conditions (Table 2). 











Gender    
Male 121 (60.5) 58 (59.8) 63 (61.2) 
Female 79 (39.5) 39 (40.2) 40 (38.8) 
Age category    
≤28 days 9 (4.5) 6 (6.2) 3 (2.9) 
>28 days – 12 months 89 (44.5) 50 (51.5) 39 (3.79) 
>12 months - <60 months 47 (23.5) 20 (20.6) 27 (26.2) 
≥60 months 55 (27.5) 21 (21.6) 34 (33.0) 
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Median age in months (IQR) 12 (2-68) 7 (2-45) 18 (4-82) 
Median (IQR) days in hospital before 
enrolment  4 (2-9) 5 (2-12) 3 (2-7) 
HIV status    
   Infected 7 (3.5) 4 (4.1) 3 (2.9) 
   Exposed, uninfected 39 (19.5) 16 (16.5) 23 (22.3) 
   Unexposed, uninfected 107 (53.5) 65 (67.0) 42 (40.8) 
   Unknown 47 (23.5) 12 (2.4) 35 (34.0) 
Primary clinical diagnosis    
Pneumonia 64 (32.0) 33 (34.0) 31 (30.1) 
Bone and soft tissue infection 20 (10.0) 7 (7.2) 13 (12.6) 
Acute diarrhoeal disease 11 (5.5) 8 (8.2) 3 (2.9) 
Central nervous system malformation 10 (5.0) 6 (6.2) 4 (3.9) 
Appendicitis 8 (4.0) 1 (1.0) 7 (6.8) 
Meningitis 8 (4.0) 2 (2.1) 6 (5.8) 
Urogenital malformations 7 (3.5) 2 (2.1) 5 (4.9) 
Hydrocephalus 7 (3.5) 0 (0.0) 7 (6.8) 
Hirschsprung disease 5 (2.5) 2 (2.1) 3 (2.9) 
Trauma 5 (2.5) 2 (2.1) 3 (2.9) 
Neonatal sepsis 4 (2.0) 4 (4.1) 0 (0.0) 
Inguinal hernia 4 (2.0) 2 (2.1) 2 (1.9) 
Tuberculosis 3 (1.5) 1 (1.0) 2 (1.9) 
Solid tumour 3 (1.5) 2 (2.1) 1 (1.0) 




Table 2: Factors associated with extended spectrum beta-lactamase-producing 
Enterobacterales colonisation determined by univariate analyses and binomial logistic 
regression 







OR (95% CI) aOR (95% CI) 
Male gender 38 (39.6) 41 (39.4) 1.01 (0.57-1.78)  
Age < 12 months 55 (57.3) 43 (41.3) 1.90 (1.09-3.34) * 1.36 (0.70-2.65) 
Transferred to RCWMCH 10 (10.4) 9 (8.7) 1.23 (0.48-3.16)  
Previous RCWMCH 
admission 
23 (24.0) 15 (14.4) 1.87 (0.91-3.84) 1.23 (0.52-2.91) 
Current admission to medical 
ward (vs. surgical ward) 
63 (65.6) 49 (47.1) 2.14 (1.21-3.79) * 0.78 (0.35-1.77) 
Hospitalisation for >7 days 
before enrolment 
40 (41.7) 20 (19.2) 3.0 (1.59-5.66) * 2.83 (1.40-5.72) * 
Cardiac co-morbidity 8 (8.3) 4 (3.8) 2.27 (0.66-7.81)  
Gastrointestinal tract co-
morbidity 
20 (20.9) 22 (21.2) 0.98 (0.50-1.94)  
Neurological co-morbidity 17 (17.7) 16 (15.4) 1.18 (0.56-2.50)  
Concomitant chronic lung 
disease 
7 (7.3) 3 (2.9) 2.65 (0.67-10.55) 2.67 (0.57-12.59) 
Concomitant congenital 
anomaly 
25 (26.0) 25 (24.0) 1.11 (0.59-2.11)  
36 
 
Major surgery in current 
admission 
12 (12.5) 23 (22.1) 0.50 (0.24-1.08) 0.40 (0.15-1.04) 
Peripheral venous line 88 
(91.7.7) 
87 (83.7) 2.15 (0.88-5.24) 1.81 (0.65-5.02) 
Nasotracheal intubation ± 
ventilation 
8 (8.3) 4 (3.8) 2.27 (0.66-7.81)  
PEG feeding  6 (6.2) 1 (1.0) 6.87 (0.81-58.1)  
Nasogastric intubation 38 (39.6) 24 (23.1) 2.18 (1.18-4.03) * 1.60 (0.76-3.39) 
Decreased level of 
consciousness 
5 (5.2) 1 (1.0) 5.66 (0.65-49.3)  
Receiving gastric acid 
inhibitor therapy 
12 (12.5) 6 (5.8) 2.33 (0.84-6.49)  
Receiving 
immunosuppressive therapy 
11 (11.2) 11 (10.6) 1.09 (0.45-2.65)  
Admission to ICU in 12 
months preceding current 
admission 
6 (6.2) 2 (1.9) 3.40 (0.68-17.27)  
Admission to ICU during 
current admission 
19 (19.8) 15 (14.4) 1.46 (0.70-3.08)  
Antibiotic administration in 
the 12-month period 
preceding admission 
29 (30.2) 21 (20.2) 1.71 (0.90-3.27) 1.35 (0.63-2.90) 
*p<0.05 
OR Odds ratio, 95% CI 95% confidence interval, aOR adjusted Odds ratio, RCWMCH Red Cross War Memorial Children’s Hospital, 
PEG percutaneous endoscopic gastrostomy, ICU intensive care unit. 
Nine percent (18/200) of the enrolled children were transferred-in from another healthcare 
facility, primarily to the medical wards at RCWMCH, 72.2% (13/18). The median duration 
of hospital stay at the time of enrolment was 4 days (range 1-64 days) and 30% of the patients 
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had been hospitalised for more than 7 days prior to enrolment (Table 2). About a third of the 
patients, 32.5% (65/200), had been admitted into other wards in the course of the current 
admission, aside from the wards in which they were enrolled during the study, and the 
majority of these children were enrolled in the medical wards, 96.9% (63/65). Of the children 
admitted into other wards before enrolment, 52.3% (34/65) had been treated in the ICU. In 
all, 19% (38/200) had been treated in the ICU at RCWMCH either in the current admission 
or in the preceding 12 months (Table 2).  
Overall, 25% (50/200) of the participants reported antibiotic usage in the 12-month period 
before current hospitalisation, 29.9% (29/97) of colonised children and 20.4% (20/103) of 
non-colonised children. The most common antibiotics administered during this period were 
penicillins in 15.0% (30/200) of children, while 4.5% (9/200) received a carbapenem. During 
the current admission, 80.5% (165/200) had received one or more antibiotics, 84.5% (82/97) 
of colonised children and 76.7% (79/103) of non-colonised children. The antibiotics that 
these children received during the current period of hospitalisation included penicillins in 
55.0% (110/200), aminoglycosides in 32% (64/200), cephalosporins in 19.5% (39/200), beta-
lactam/beta-lactam inhibitor combination in 16% (32/200), carbapenems in 9% (18/200), 
cotrimoxazole in 7.5% (15/200), macrolides in 5.5% (11/200), metronidazole in 4.0% (8/200) 
and fluoroquinolones in 3.0% (6/200). 
Factors associated with ESBL-PE colonisation 
Using univariate analysis, age less than 12 months, admission to a medical ward at the time 
of study enrolment, hospitalisation for more than 7 days before study enrolment, and 
nasogastric intubation at the time of enrolment were significantly associated with ESBL-PE 
colonisation. However, on binomial logistic regression analysis, only hospitalisation for more 
than 7 days before study enrolment remained significantly associated with ESBL-PE 
colonisation (p=0.013) (Table 2).    
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Antibiotic susceptibility profile of the ESBL-PE and CRE isolates 
Table 3 summarises the antibiotic susceptibility profiles of the 104 ESBL-PE isolates.  All 
ESBL-PE isolates were resistant to the cephalosporins except for one E. coli isolate and one 
E. cloacae isolate which retained susceptibility to cefepime, using Vitek 2. All the ESBL-PE
isolates were however susceptible to the carbapenems and colistin. Most of the K. 
pneumoniae (72.3%) were susceptible to piperacillin/tazobactam and to amikacin (86.2%). 
Similarly, 94.4% and 97.2% of the E. coli isolates were susceptible to piperacillin/tazobactam 
and amikacin, respectively (Table 3). Susceptibility to both piperacillin/tazobactam and 
amikacin was observed in 73.1% of all isolates, 64.6% and 91.7% of all ESBL-PE K. 
pneumoniae and E. coli isolates respectively. The CRE E. cloacae isolate exhibited 
intermediate susceptibility to ertapenem on E-test, but was susceptible to imipenem and 
meropenem. 
Table 3: Antibiotic susceptibility profile of the extended spectrum beta-lactamase-



















Cotrimoxazole 10 (9.6) 5 (7.7) 4 (11.1) 0 (0.0) 1 (100.0) 
Ampicillin / 
amoxicillin 
1 (1.0) 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 
Amoxicillin plus 
clavulanic acid 
19 (18.3) 1 (1.5) 16 (44.4) 2 (100.0) 0 (0.0) 
Piperacillin plus 
tazobactam 
83 (79.8) 47 (72.3) 34 (94.4) 2 (100.0) 0 (0.0) 
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Cefepime 2 (1.9) 0 (0.0) 1 (2.8) 0 (0.0) 1 (100.0) 
Ciprofloxacin 687 (64.4) 41 (63.1) 23 (63.9) 2 (100.0) 1 (100.0) 
Gentamicin 33 (31.7) 8 (12.3) 22 (61.1) 2 (100.0) 1 (100.0) 
Amikacin 93 (89.4) 56 (86.2) 35 (97.2) 1 (50.0) 1 (100.0) 
Tigecycline 104 (100.0) 65 (100.0) 36 (100.0) 2 (100.0) 0 (0.0) 
 
Genetic testing of ESBL-PE and CRE Isolates 
Of the 104 ESBL-PE and 1 CRE isolated from 97 colonised children, 94 isolates from 87 
patients were available for genetic testing. Eighty ESBL-PE isolates (85.1%) from 73 patients 
had one or more resistance-conferring genes (Table 4). Of these, 25% (20/80) had only one 
resistant-conferring gene, 14 (17.5%) had 2 genes, and 46 (57.5%) had 3 genes identified. 
The most common resistance conferring gene was blaCTX-M found in 95% (76/80) of ESBL-
PE i.e. in 98.2% (56/57) of K. pneumoniae isolates, 55.9% (19/34) of E. coli isolates, and the 
only K. oxytoca (1.3%) isolate tested. The blaTEM and blaSHV genes were found in 66.3% 
(53/80) and 13.8% (11/80) of ESBL-PE isolates respectively, often in combination with 
blaCTX-M gene.  Three E. coli isolates had blaTEM as the only resistance gene, and one K. 
pneumoniae isolate had blaSHV as the only resistance gene. The 3 E. coli TEM-only positive 
amplicons were sequenced, and two were identified as TEM-1 genotypes i.e. narrow-
spectrum beta-lactamase, and the remaining one as a TEM-135 genotype i.e. ESBL. The 
DNA from the SHV-only positive K. pneumoniae isolate was not sequenced as blaSHV is 
intrinsic to K. pneumoniae and would not be differentiated using conventional sequencing. 
For the two ESBL-PE isolates which retained susceptibility to cefepime, no gene was found 





Table 4: Frequency of genes conferring extended spectrum beta-lactam resistance to 
the colonising extended spectrum beta-lactamase-producing Enterobacterales isolates  

















Not available 8 2 1 0 11 
No gene found 0 12 0 1 13 
No EBSL gene confirmed 
TEM 1 only 0 2 0 0 2 
SHV 1 only 1 0 0 0 1 
EBSL gene confirmed 
TEM-135 only 0 1 0 0 1 
CTX-M only 0 16 0 0 16 
CTX-M + TEM 1 2 1 0 4 
CTX-M + SHV 10 0 0 0 10 
TEM + SHV 0 0 0 0 0 
CTXM + TEM + 
SHV 
45 1 0 0 46 
ESBL-PE, extended spectrum beta-lactamase-producing Enterobacteriaceae, ESBL, extended spectrum beta-lactamas 
e, CTX-M, cefotaxime-hydrolyzing beta-lactamase, TEM, Temoneira resistance encoding genes, SHV, sulphydryl variable  
The only CRE isolate, an E. cloacae, was negative for common CRE conferring genes, 





In this prospective cross-sectional study, we showed that approximately 50% of children 
hospitalised in RCWMCH are colonised with ESBL-PE, predominately with K. pneumoniae 
and E. coli, findings which are consistent with previous paediatric colonisation studies [12, 
13, 51].  The CRE colonisation prevalence was extremely low in our patients, but comparable 
to previous studies which also reported lower CRE colonisation [31, 35, 52]. Similarly, 
bloodstream infection (BSI) studies from our hospital have shown that while K. pneumoniae 
and E. coli are the predominant Gram-negative aetiological agents, CRE only sporadically 
caused invasive infection [45, 53]. Furthermore, of K. pneumoniae and E. coli isolates 
causing BSI at RCWMCH, 83% and 30% are ESBL-PE, respectively [42, 43].  
This study was not designed to determine the timing of colonisation of ESBL-PE and CRE 
and hence we were unable to establish the extent of community versus hospital acquisition. 
Colonisation was documented in some patients who had only been hospitalised for one day, 
suggesting that some of the patients may have been colonised outside the hospital 
environment. However, the risk factor analysis showed that hospitalisation for more than 7 
days before enrolment was an independent risk factor for ESBL-PE colonisation. This finding 
strongly suggests that the healthcare environment is an important site of colonisation and is 
consistent with previous BSI studies that showed that 95% and 55% of K. pneumoniae and 
E. coli BSIs respectively are hospital-acquired or healthcare-associated [42, 43]. 
The predominant ESBL gene identified was blaCTX-M (95%), often occurring in combination 
with other ESBL-conferring genes (78.9%). This was notable for the K. pneumoniae isolates, 
most of which carried more than one ESBL-conferring gene. In contrast, most E. coli isolates 
harboured only the blaCTX-M gene. This is in keeping with the global pattern where CTX-M 
has become the predominant ESBL-conferring gene in resistant K. pneumoniae and E. coli 
isolates [4, 21, 27]. It has been suggested that the CTX-M plasmid has adapted to K. 
pneumoniae resulting in better transmission efficiency [4, 27]. Three E. coli isolates each 
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harboured a TEM gene only. One isolate had a TEM-135 gene which encodes an enzyme 
that hydrolyses 3rd generation cephalosporins and thus confers ESBL-PE properties on the 
isolate [54]. This is unlike the TEM-1 gene found in the other 2 isolates, the first TEM gene 
which encodes an enzyme that hydrolyses earlier penicillins like ampicillin but not 3rd 
generation cephalosporins, and therefore does not confer ESBL-PE characteristics on the 
isolates [55]. Most K. pneumoniae isolates have chromosomal SHV genes which encodes 
enzymes that do not hydrolyse 3rd generation cephalosporins [55]. One of our K. pneumoniae 
isolates was shown to only carry an SHV gene. The ESBL-PE phenotype of the three isolates 
with TEM-1 only or SHV only genes might be due to hyperproduction of the encoded 
enzymes along with porin changes, or the presence of other ESBL’s or enzymes not detected 
by this assay.  
The antibiotic susceptibility profiles of the ESBL-PE isolates as summarised in Table 4 
correlate with published data. High proportions of the K. pneumoniae and E. coli isolates 
were susceptible to piperacillin-tazobactam and to amikacin, similar to findings among 
ESBL-producing bloodstream isolates of K. pneumoniae and E. coli reported in previous 
studies from RCWMCH [42].  Despite these findings, a randomised control trial among 
adults that determined whether piperacillin-tazobactam was as effective as meropenem for 
treating BSI caused by K. pneumoniae or E. coli with non-susceptibility to third generation 
cephalosporins showed that the 30-day mortality was significantly higher in the piperacillin-
tazobactam group, suggesting that piperacillin-tazobactam alone may no longer be the 
recommended definitive therapy in this context. The high proportion of E. coli (91.6%) 
susceptible to both piperacillin-tazobactam and amikacin suggest this may be a consideration 
in BSI caused by ESBL-PE E. coli. This is unlikely to be an option for ESBL-PE K. 





Study strengths and limitations 
A strength of this study is that it is one of the first prospective studies to estimate the 
prevalence of ESBL-PE and CRE carriage in children hospitalised in sub-Saharan Africa. 
Limited funds for completing the microbiology investigation of the enrolled patients 
restricted our surveillance to one specimen per patient and prevented us from sampling the 
patients at multiple time points during hospitalisation, and prevented differentiation between 
community and hospital acquisition of ESBL-PE. Our sampling approach may have under-
estimated the colonisation rate as multiple rectal swabs may have increased the yield of 
colonised children or serial sampling may have identified additional children who became 
colonised later on in the course of their hospital admission. The sample size of 200 children 
was not determined scientifically but influenced by the available funding. Thus, the study 
may have been underpowered to explore risk factors associated with colonisation 
definitively. Screening for genes conferring extended spectrum beta-lactam resistance was 
limited to the three commonly occurring resistance genes in our setting. Furthermore, we did 
not screen the isolates for the presence of Ambler group C beta-lactamases which produce 
similar antibiograms to the extended spectrum beta-lactamases. Lastly, relatedness of the 
ESBL-PE isolates was not evaluated. This may have assisted us to understand the extent of 
hospital transmission.  
Notwithstanding these limitations the study showed that ESBL-PE colonisation prevalence 
is high in this setting, and prolonged hospitalisation is a risk factor for colonisation, 
suggesting the need for improved infection control practices.  
 
CONCLUSION 
The current study extends our understanding of ESBL-PE and CRE colonisation at our 
institution. Major findings were high ESBL-PE colonisation prevalence, very low CRE 
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colonisation prevalence, prolonged hospitalisation as an independent risk factor for ESBL-
PE colonisation, and common resistance genes are responsible for conferring extended 
spectrum beta-lactam resistance. Further research is required to explore colonisation 
prevalence changes over time, quantify the extent of community versus hospital acquisition, 
determine relatedness of the isolates, and determine whether improved infection control 
practice can moderate colonisation rates.      
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Supplementary Table 1 
References for ESBL and Carbapenemase PCR 
Primer Sequence 5' - 3' Length Reference 
CARBAPENEMASES 
GesF ATGCGCTTCATTCACGC 17 [1] 
GesR GCTCAGGATGAGTTGTG 17 [1] 
ImpXF2 ATTGACACTCCATTTAC 17 [2] 
ImpXR2 AACAACCAGTTTTGC 15 [2] 
NdmF2 GGTTTGGCGATCTGGTTTTC 20 [3] 
NdmR2 CGGAATGGCTCATCACGATC 20 [3] 
Oxa48F CGTGTATTAGCCTTATCG 18 [3] 
Oxa48R CGCTAACCACTTCTAGG 17 [3] 
VimXF GTGAGTATCCGACAGTC 17 [2] 
VimXR GAGCAAGTCTAGACCG 16 [2] 
KpcF TGTCACTGTATCGCCGTC 18 [4] 
KpcR CTCAGTGCTCTACAGAAAACC 21 [4] 
ESBL’s 
CTXM1F CGCTTTGCGATGTGCAG 17 [1] 
CTXM1R ACCGCGATATCGTTGGT 17 [1] 
SHVC AGAAGGGTTATTCTTATTTGTCGC 24 [5] 
SHVD TCTTTCCGATGCCGCCGCCAGTCA 25 [5] 
DEB ATGAGTAAACTTGGTCTGAC 20 [6] 
3061TEM AGGAAGCAAAGCTGAAAGGAATCAAATTTGG 31 [1] 
New Delhi Metallo-beta-lactamase (NDM), Klebsiella pneumoniae carbapenemase (KPC), Oxacillinase-48 (OXA-48) and variants, 
Imipenemase (IMP), Verona Integron-Mediated Metallo-beta-lactamase (VIM) and Guiana extended spectrum carbapenemase (GES). 






1. Segal H, Elisha BG. Resistance to beta-lactams, and reduced susceptibility to 
carbapenems, in clinical isolates of Klebsiella pneumoniae due to interplay between CTX-
M-15 and altered outer membrane permeability. The South African Journal of 
Epidemiology and Infection. 2006;21(2):41-4. 
2. Jacobson RK, Minenza N, Nicol M, Bamford C. VIM-2 metallo-beta-lactamase-
producing Pseudomonas aeruginosa causing an outbreak in South Africa. J Antimicrob 
Chemother. 2012;67(7):1797-8. doi: 10.1093/jac/dks100. PubMed PMID: 22457310. 
3. Manesen R, Bamford C, Smith M, Jacobson R, Moodley C, Williams S. Outbreak 
of carbapenem-resistant Klebsiella sp. in an academic hospital, Western Cape, May 2012. 
NationaI Institute for Communicable Diseases Surveillance Bulletin. 2012;10(4):82-6. 
4. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward 
CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-
resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151-
61. doi: 10.1128/AAC.45.4.1151-1161.2001. PubMed PMID: 11257029; PubMed Central 
PMCID: PMCPMC90438. 
5. Wang H, Kelkar S, Wu W, Chen M, Quinn JP. Clinical Isolates of 
Enterobacteriaceae Producing Extended-Spectrum β-Lactamases: Prevalence of CTX-M-3 
at a Hospital in China. Antimicrobial Agents and Chemotherapy. 2003;47(2):790-3. doi: 
10.1128/aac.47.2.790-793.2003. 
6. Canica MM, Lu CY, Krishnamoorthy R, Paul GC. Molecular diversity and 
evolution of blaTEM genes encoding beta-lactamases resistant to clavulanic acid in clinical 
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# ESBL-PE, Extended spectrum beta-lactamase producing Enterobacterales, CRE, Carbapenem-resistant Enterobacterales, CTX-M, 
Cefotaxime-hydrolyzing beta-lactamase, TEM, Temoneira resistance encoding genes, SHV, Sulfhydryl variable, K. pneumoniae - 




77 isolates had one or more ESBL encoding 
gene isolated 
299 children selected for enrolment 
103 patients not colonised with 
ESBL-PE or CRE 
96 patients colonised with 104 ESBL-PE and 
1 patient with CRE isolate. 
*8 patients had 2 ESBL-PE isolates each. 
99 excluded:  
- 39 Declined consent  
- 26 Discharged before 
enrolment  
- 24 No parent/legal guardian 
to give consent  
- 10 Caregiver without legal 
rights to give consent  
11 isolates from 10 patients 
were not recoverable, thus not 
available for genetic testing 
 
200 enrolled into the study 
94 isolates from 87 patients were available 
for genetic testing. 
17 isolates had none of the 
common ESBL (14 E. coli, 1 
K. pneumoniae and 1 E. 
cloacae) or CRE (the E. 
cloacae) genes tested. 
CTXM + TEM:  
1 K. pneumoniae, 2 E. 
coli and 1 K. oxytoca 
isolate 
CTXM + TEM + SHV: 
45 K. pneumoniae and 1 
E. coli isolate 
TEM-135 
only: 
1 E. coli 
isolate 
CTXM only: 
16 E. coli 
isolates 
CTXM + SHV: 






ESBL-PE AND CRE RECTAL COLONISATION DATA COLLECTION FORM 
ADMISSION DETAILS / DEMOGRAPHICS AND ANTHROPOMETRY 
 





2. Date enrolled:     …… /……. /……….  
(DD/MM/YYYY)      
 
3. Date admitted:   ....../……./…………  
(DD/MM/YYYY)      
 
4. Weight (Kg):  ………………………… 
 
5. Height (cm): ………………………… 
 
6. Gestational age at birth   
………………………………….. 
 
7. Birth weight (gm) …………………… 
 
8. Transferred in  
 
Yes[1]    No[2] 
 
9. Source of admission …………………… 
 
10. Duration of stay at Source of admission .....days 
 
11. Previous ESBL-PE Infection(s): Yes[1]   
No[2] 
 
12. If Yes to No. 14 
 
13. Type of Previous ESBL-PE Infection(s):  
 










19. Previous CRE Infection(s): Yes [1]   No [2] 
 
 
20. If Yes to No. 22 
 
21. Type of Previous CRE Infection(s):  
 










27. Ward admitted into 
……………. 
 
28. Residence on other wards in this 
hospital  Yes [1] No [2] 
 




30. Date rectal swab 
collected…../…./…(DD/MM/YYYY)      
 
31. Date of outcome      
....../……./……(DD/MM/YYYY) 
 
32. Outcome: Discharged home [1], Transferred out [2], Died [3] 
 
33. Any Red Cross War Memorial Children’s Hospital admission in the last 1year?    Yes [1] No [2] 
 




Ward(s) admitted into 
 














39. ……… /……. /………..  to  ....../……./……… 
(DD/MM/YYYY) 
 
RISK FACTORS FOR COLONIZATION 
 










41. Neurological  
 
Yes 




















44. Malignancy  
 
Yes 








[1]    
 
No [2] 
46. Genetic   
Yes 
































50. Endocrine  
 
Yes 








[1]    
 
No [2] 
52. Surgical  
Yes 













54. If yes, specify  <1 Month [1] 
 ≥ 1 Month [2] 
 
55. Specify details of co-morbid medical 
condition(s) 
 





















64. Viral Load (Last 6mo) 
 
……………/ Log ……… 
65. CD4 (Last 6mo)   
 
…….……./……..% 
Co-morbid Surgical Condition 
66. Surgery in the past 
 
Yes [1] No [2] 67. *Type: Minor [1] 
                  Major [2] 
68. Specify name and date:    
 _______________________ 
69. Surgery in this 
admission 
 
Yes [1]    No [2] 70. *Type: Minor [1] 
                  Major [2] 
71. Specify type and date:  
     _____________________ 




Yes [1]    No [2] 73.  Urethral 
catheter 
Yes 
[1]    
No [2] 74. PD 
catheter 
Yes 









[1]    
No [2]   
77. PEG tube 
feeding 





[1]    
No [2] 79. If yes, specify    
_______________ 
80. If yes, duration 
        <1Month [1],   ≥ 1 Month [2] 
81. If yes, duration  
        <1 Month [1],    ≥ 1 Month 
[2] 
Other risk factors during current admission 










83. If yes, specify type of 
inhibitor 
_____________________ 
84. Duration of use of 
inhibitor 
    < 1 Month [1]  
    ≥ 1 Month [2] 
 
85. Neutropenia  
 
Yes 




86. <500cell/mm3 [1], 500-1000cell/mm3 [2], >1000cell/mm3 
[3] 
 













……… /……. /………..  to  ....../……./……… (DD/MM/YYYY) 
 
……… /……. /………..  to  ....../……./……… (DD/MM/YYYY) 
 






……… /……. /………..  to  ....../……./……… (DD/MM/YYYY) 
 








94. Pre-admission antibiotic exposure in the last 1 Year:  Yes[1]   No[2] 
If yes:  




 Duration of use 
95. Carbapenem      
96. 2nd Gen. Cephalosporin     
97. 3rd Gen. Cephalosporin     
98.  Penicillin     
99. Fluoroquinolone     
100. Macrolide      
101. Aminoglycoside     
102. Cotrimoxazole     
103. Piperacillin/Tazobactam     
104. Others…………..     
     
105. Antibiotic use in this admission: Yes[1]   No[2] 
If yes:  




Duration of use 
106. Carbapenem      
107. 2nd Gen. Cephalosporin     
108. 3rd Gen. Cephalosporin     
109.  Penicillin     
110. Fluoroquinolone     
111. Macrolide      
112. Aminoglycoside     
113. Cotrimoxazole     
114.Piperacillin/Tazobactam     








116. ID of Rectal swab isolate ESBL  CRE  
Yes [1]    No [2] Yes [1]    No [2] 
     
     
117. Molecular typing (MT) and MICs of Isolates 
ID of Isolate MT Antibiotic MIC Susceptibility 
S[1]  I[2]  R[3] 
  
       
       
       
       
       
       
       
       
       
       
* Minor surgery is any invasive operative procedure in which only skin or mucus membranes and connective tissue is resected e.g. vascular 
cut-down for catheter placement, implanting pumps in subcutaneous tissue. Major surgery is any invasive operative procedure in which 
a more    extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if 
a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major. Ref: 












INFORMED CONSENT FORM FOR PARENT(S)/GUARDIAN 
IRB research approval number: IRB00001983 
Title of the Research: Epidemiology of ESBL and CRE Colonization in Children 
admitted to Red Cross War Memorial Children’s Hospital, Cape Town 
Name and affiliation of Researcher: This study is being conducted by Dr Babatunde 
Ogunbosi, a Senior Registrar in Infectious Diseases Unit of the Department of Paediatrics 
and Child Health, Red Cross Children’s Hospital under the supervision of Prof Brian Eley, 
Department of Paediatrics and Child Health, Red Cross Children’s Hospital.  
Sponsor of the Research: The investigator Dr Ogunbosi is being funded by the APFP which 
help to provide sub-specialty clinical and research training for paediatricians in Africa.  
Purpose of Research: The purpose of this research is to describe the frequency and spectrum 
of multi-drug resistant enterobacteriaceae that colonize the gastrointestinal tracts of children 
hospitalised in Red Cross War Memorial Children’s Hospital (RCWMCH), Cape Town, and 
to evaluate risk factors associated with colonized children. Multi-drug resistant 
enterobacteriaceae are bacteria which usually reside in the gut and are resistant to some of 
the antibiotics that are used to treat serious infections. They can exist in the gut without 
causing infection, so the child is not sick from these organisms, this is called colonization. 
Some children can later develop infections from these organisms, which can be very difficult 
to treat. This research will determine the proportion of children carrying these organisms in 
their gastrointestinal tracts, but who are not sick from the organisms. The study will describe 
the characteristics of children who get colonized and also the risk factors associated with 
colonization. It will assist in easy identification, in future, of children that will be mostly 
colonized and therefore monitor them appropriately, as well as implement ways to prevent 
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spread to other children. It may also provide information on how to prevent other children 
from being colonized.  
Procedure of the Research: Parents / guardians of children admitted to medical and surgical 
wards of the hospital will be approached for recruitment into the study. With your kind 
permission we will collect information with regards antibiotic use by your child/ward in the 
past year, and hospital admission or residence in a non-acute care health facility. Also 
information on admission into the intensive care unit and other areas in this hospital will be 
collected. In addition, information on the treatment given, especially antibiotics, in this 
admission, surgical and other procedures will also be collected. 
 
Stool will be collected with rectal swabs/stool sample. A rectal swab has a sterile cotton wool 
mounted on a thin flexible plastic holder which does not cause pain nor harm. The sterile 
cotton wool on the rectal swab will be inserted into your child/ward’s anus, the stool on it 
will be tested for the organisms mentioned earlier. If the stool on the rectal swab is not 
sufficient, then a bit of your child/ward’s stool will be collected in a clean germ free 
container. No blood samples will be collected.  
We hope to enroll about 200 children over the 8 - 12 month duration of the study. 
 
Expected duration of research and of participant’s involvement: Your child/ward will be 
involved when the rectal swab/stool sample is collected. The rectal swab/stool collection 
procedure will only take about 2-3minutes. However, we will continue to monitor his/her 
course in the hospital to update information being collected as part of the study. 
Risks:  The procedure is neither painful nor harmful in any way to your child/ward. Your 
child/ward might experience some discomfort as the rectal swab is being taken. We will 
ensure we do all we can to make the process most comfortable for your child/ward. We will 
also be available to address your questions and worries. 
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Costs: The cost of rectal swab/stool sample collection and testing will be borne by the 
research team, so overall there is no additional cost to you.  
Benefits: Results of these tests will be promptly made available to you and the doctors for 
your child/ward’s care. It will also assist the doctors to care better for other children in future. 
If your child/ward is colonized with a multi-drug resistant bacterium, we will teach you how 
to prevent spread to other members in your household.  
Confidentiality: We will maintain utmost confidentiality at all times about information 
collected for this research. The information that we collect from you and entered into the 
computer for analysis will not be linked to your child/ward in anyway and your child/ward’s 
name or any identifier, and will not be used in any publication or reports from this study. As 
part of our responsibility to conduct this research properly, officials from the University of 
Cape Town’s Human Research Ethics Committee may have access to these records.  
Voluntariness: Your participation in this study is entirely voluntary and you may also choose 
to withdraw at any stage of the study. 
Alternatives to participation: If you choose not to participate, your child/ward will still 
receive all necessary treatment and it will not affect your child’s right to receive treatment in 
the department or hospital in any way.  
Consequences of participants’ decision to withdraw from research and procedure for 
orderly termination of participation: 
You are free to refuse to take part in this programme. You also have the right to withdraw at 
any given time if you choose. 
Please note that some of the information that has been obtained about you and your 
child/ward before you chose to withdraw may have been used in reports and publications. 
These cannot be removed anymore. However, we promise to make sincere efforts to comply 




What happens to research participants and communities when the research is over:  
If you so wish, the researchers will inform you of the outcome of this research. However 
during the course of this research, you will be informed about any findings that may affect 
your child/ward’s health. 
 
Detailed contact information including contact address, telephone, fax, E-mail and any 
other contact information of the researcher, institutional IRB and head of institution: 
This research has been approved by the Ethics Committee of the University of Cape Town 
and the HREC Convener can be reached at Prof Mark Blockman, E53, Ground Floor, Old 
Main Building, Groote Schuur Hospital, Observatory, Cape Town.  
In addition, if you have any question about your participation in this research, you can contact 
the; 
1. Investigator:                           Dr. Babatunde O. Ogunbosi    
     Infectious Diseases Unit  




2. Supervisor:    Prof Brian Eley     
     Infectious Diseases Unit  






PLEASE KEEP A COPY OF THE SIGNED INFORMED CONSENT 
CONSENT: 
Statement of parent/guardian giving consent: 
I have read the description of the research or have had it translated into the language I 
understand. I have also talked it over with the doctor to my satisfaction. I understand that my 
child’s participation is voluntary. I know enough about the purpose, methods, risks and 
benefits of the research study to judge that I want to take part in it. I understand that I may 
freely stop my child being part of this study at any time. I have received a copy of this consent 




Statement of person obtaining informed consent: 
I have fully explained this research to __________________________________ and have 







INFORMED CONSENT FORM FOR ADOLESCENTS 
IRB research approval number: IRB00001983 
Title of the Research: Epidemiology of ESBL and CRE Colonization in Children 
admitted to Red Cross War Memorial Children’s Hospital, Cape Town 
Name and affiliation of Researcher: This study is being conducted by Dr Babatunde 
Ogunbosi, a Senior Registrar in Infectious Diseases Unit of the Department of Paediatrics 
and Child Health, Red Cross Children’s Hospital under the supervision of Prof Brian Eley, 
Department of Paediatrics and Child Health, Red Cross Children’s Hospital.  
Sponsor of the Research: The investigator Dr Ogunbosi is being funded by the APFP which 
help to provide sub-specialty clinical and research training for paediatricians in Africa.  
Purpose of Research: The purpose of this research is to describe the frequency and spectrum 
of multi-drug resistant enterobacteriaceae that colonize the gastrointestinal tracts of children 
hospitalised in Red Cross War Memorial Children’s Hospital (RCWMCH), Cape Town, and 
to evaluate risk factors associated with colonized children. Multi-drug resistant 
enterobacteriaceae are bacteria which usually reside in the gut and are resistant to some of 
the antibiotics that are used to treat serious infections. They can exist in the intestine without 
causing infection, so the child is not sick from these organisms, this is called colonization. 
Some children can later develop infections from these organisms, which can be very difficult 
to treat. This research will determine the proportion of children carrying these organisms in 
their intestine, but who are not sick from the organisms. The study will describe the 
characteristics of children who get colonized and also the risk factors associated with 
colonization. It will assist in easy identification, in future, of children that will be mostly 
colonized and therefore monitor them appropriately, as well as implement ways to prevent 
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spread to other children. It may also provide information on how to prevent other children 
from being colonized.  
Procedure of the Research: Parents / guardians of children admitted to medical and surgical 
wards of the hospital and the adolescent will be approached for recruitment into the study. 
With your kind permission we will collect information with regards antibiotic you have 
received in the past year, and hospital admission or residence in a non-acute care health 
facility. Also, information on admission into the intensive care unit and other areas in this 
hospital will be collected. In addition, information on the treatment given, especially 
antibiotics, in this admission, surgical and other procedures will also be collected. 
Stool will be collected with rectal swabs/stool sample. A rectal swab has a sterile cotton wool 
mounted on a thin flexible plastic holder which does not cause pain nor harm. The sterile 
cotton wool on the rectal swab will be inserted into your anus, the stool on it will be tested 
for the organisms mentioned earlier. If the stool on the rectal swab is not sufficient, then a bit 
of your stool will be collected in a clean germ-free container. No blood samples will be 
collected. We hope to enroll about 200 children over the 8 – 12 month duration of the study. 
Expected duration of research and of participant’s involvement: You will be involved 
when the rectal swab/stool sample is collected. The rectal swab/stool collection procedure 
will only take about 2-3minutes. However, we will continue to monitor you in the course of 
hospital stay to update information being collected as part of the study. 
Risks:  The procedure is neither painful nor harmful in any way to you. You might experience 
some discomfort as the rectal swab is being taken. We will ensure we do all we can to make 
the process most comfortable for you. We will also be available to address your questions 
and worries. 
Costs: The cost of rectal swab/stool sample collection and testing will be borne by the 
research team, so overall there is no additional cost to you or your parent/guardian.  
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Benefits: Results of these tests will be promptly made available to you and the doctors for 
your care. It will also assist the doctors to care better for other children in future. If you are 
colonized with a multi-drug resistant bacterium, we will teach you and your parent/guardian 
how to prevent spread to other members in your household.  
Confidentiality: We will maintain utmost confidentiality at all times about information 
collected for this research. The information that we collect from you and entered into the 
computer for analysis will not be linked to you in anyway and your name or any identifier, 
and will not be used in any publication or reports from this study. As part of our responsibility 
to conduct this research properly, officials from the University of Cape Town’s Human 
Research Ethics Committee may have access to these records.  
Voluntariness: Your participation in this study is entirely voluntary and you may also choose 
to withdraw at any stage of the study. 
Alternatives to participation: If you choose not to participate, you will still receive all 
necessary treatment and it will not affect your right to receive treatment in the department or 
hospital in any way.  
Consequences of participants’ decision to withdraw from research and procedure for 
orderly termination of participation: 
You are free to refuse to take part in this programme. You also have the right to withdraw at 
any given time if you choose. 
Please note that some of the information that has been obtained about you before you chose 
to withdraw may have been used in reports and publications. These cannot be removed 
anymore. However, we promise to make sincere efforts to comply with your wishes as much 
as is possible. 
What happens to research participants and communities when the research is over:  
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If you so wish, the researchers will inform you of the outcome of this research. However, 
during the course of this research, you will be informed about any findings that may affect 
your health. 
Detailed contact information including contact address, telephone, fax, E-mail and any 
other contact information of the researcher, institutional IRB and head of institution: 
This research has been approved by the Ethics Committee of the University of Cape Town 
and the HREC Convener can be reached at Prof Mark Blockman, E53, Ground Floor, Old 
Main Building, Groote Schuur Hospital, Observatory, Cape Town.  
In addition, if you have any question about your participation in this research, you can contact 
the; 
1. Investigator:                        Dr. Babatunde O. Ogunbosi    
     Infectious Diseases Unit  




2. Supervisor:    Prof Brian Eley     
                Infectious Diseases Unit  




PLEASE KEEP A COPY OF THE SIGNED INFORMED CONSENT 
CONSENT: 
Statement of adolescent giving consent: 
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I have read the description of the research or have had it translated into the language I 
understand. I have also talked it over with the doctor to my satisfaction. I understand that my 
participation is voluntary. I know enough about the purpose, methods, risks and benefits of 
the research study to judge that I want to take part in it. I understand that I may freely stop 
being part of this study at any time. I have received a copy of this consent form and additional 
information sheet to keep for myself. 
NAME: ___________________________________ 
SIGNATURE: _______________________________ 
DATE: ____________________________________                                                            
Statement of person obtaining informed consent: 
I have fully explained this research to __________________________________ and have 
given sufficient information, including risks and benefits to make an informed decision. 
NAME: ___________________________________ 
SIGNATURE: ______________________________ 












INFORMED ASSENT FORM FOR CHILDREN AGED 7 YEARS AND ABOVE 
IRB research approval number: IRB00001983  
Title of the Research: Epidemiology of ESBL and CRE Colonization in Children 
admitted to Red Cross War Memorial Children’s Hospital, Cape Town 
Name and affiliation of Researcher: My name is Dr Babatunde Ogunbosi, a Senior 
Registrar in Infectious Diseases Unit of the Department of Paediatrics and Child Health, Red 
Cross Children’s Hospital working under the supervision of Prof Brian Eley, Department of 
Paediatrics and Child Health, Red Cross Children’s Hospital. Our job is to prevent infections 
in children and also to take care of children who get infections so they can get well again. 
Sponsor of the Research: The investigator, Dr Ogunbosi, is being funded by the APFP 
which help to provide sub-specialty clinical and research training for paediatricians in Africa.  
Introduction and purpose of study: We will be asking you to take part in this study. We 
have also spoken to your parent/guardian about the study and they are also aware we will be 
asking you take part in this study. Their consent is also needed for you to take part in the 
study, but should you decline to be part of the study, we will respect your decision and will 
not include you in the study. You may choose to discuss this over with your parents or friends, 
and if you need further information about the study, feel free to seek clarification from us or 
any doctor at any point in the study.  
The purpose of this research is to describe the frequency and spectrum of multi-drug resistant 
bacteria called enterobacteriaceae that colonise the gastrointestinal tracts of children 
hospitalised in Red Cross War Memorial Children’s Hospital (RCWMCH), Cape Town, and 
to evaluate risk factors associated with colonized children. Multi-drug resistant 
enterobacteriaceae are bugs which usually reside in the intestines and are resistant to some 
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of the antibiotics that are used to treat serious infections. They can exist in the gut without 
causing infection, so the child is not sick from these organisms, this is called colonization. 
When children develop infections from these organisms, they can be very difficult to treat. 
This research will determine the proportion of children carrying these organisms in their 
intestines, but who are not sick from the organisms. The study will describe the characteristics 
of children who carry these organisms and also the risk factors associated with that. It will 
assist in easy identification, in future, of children that will be mostly affected in such a way 
and therefore help in monitor them appropriately, as well as implement ways to prevent 
spread of the organisms to other children. It may also provide information on how to prevent 
other children from acquiring these organisms.  
Why ask you to participate in the study? 
We are carrying out the study in children, aged between 1 month and 18 years. Children 
admitted into this and other wards in Red Cross Children’s Hospital who do not already have 
infections by the organisms mentioned earlier, will be invited to take part.  
Voluntariness: Your participation in this study is entirely voluntary and you may also choose 
to opt out at any stage of the study. 
Alternatives to participation: If you choose not to participate, you will still receive all 
necessary treatment and it will not affect your right to receive treatment in this hospital in 
any way. 
Procedure of the Research: Should you decide to be part of the study, we will collect 
information with regards any antibiotic you have received in the past year and hospital 
admission or stay in a non-acute care health facility. Also, information about admission into 
the ICU and other areas in this hospital will be collected. In addition, information on the 




Stool will be collected with rectal swabs/stool sample. A rectal swab has a sterile cotton wool 
mounted on a thin flexible plastic holder which does not cause pain nor harm. The sterile 
cotton wool on the rectal swab will be inserted into your anus. The stool on it will be tested 
for the organisms mentioned earlier. If the stool on the rectal swab is not sufficient, then a bit 
of your stool will be collected in a clean germ-free container. No blood samples will be 
collected.  
Expected duration of research and of participant’s involvement: We will be collecting 
information about you for this research throughout the course of your admission in this 
hospital. However, the rectal swab/stool sample collection procedure takes only about 2-
3minutes. We hope to enroll about 200 children over the 8-12 month duration of the study. 
Risks:  The rectal swab/stool sample collection procedure is neither painful nor harmful in 
any way. You might experience some discomfort. We will ensure we do all we can to make 
the process most comfortable for you. We will take all standard precautions to ensure that we 
do not pass infection to you and we will be available to address your questions and worries. 
Benefits: Results of these tests will be promptly made available to your parent/guardian and 
your doctors for your care. It will also assist doctors to care better for other children in future. 
If you are colonized with a multi-drug resistant bacterium, we will teach you how to prevent 
spreading it to other members in your household. 
Confidentiality: We will maintain utmost confidentiality at all times about information 
collected for this research. The information that we collect from you and enter into the 
computer for analysis will not be linked to you and your name or any identifier, and will not 
be used in any publication or reports from this study.  
Consequences of participants’ decision to withdraw from research and procedure for 
orderly termination of participation: 
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You are free to refuse to take part in this programme. You also have the right to withdraw at 
any given time if you so choose. 
Please note that some of the information that has been obtained about you before you chose 
to withdraw may have been used in reports and publications. These cannot be removed 
anymore. However, we promise to make sincere efforts to comply with your wishes as much 
as is possible. 
What happens to research participants and communities when the research is over?  
If you so wish, the researchers will inform you and your parent/guardian of the outcome of 
this research. However, during the course of this research, you and your parent/guardian will 
be informed about any findings that may affect your health. 
Contact information:  
Should you need to contact anyone with respect to this study, we can be reached at Dr. 
Babatunde O. Ogunbosi, African Paediatric Fellowship Programme, Department Of 
Paediatrics And Child Health, Red Cross Children’s Hospital, Klipfontein Road, 5th Floor, 
ICH Building, Rondebosch, 7700. Telephone: 0743496244 Email: 
tundeogunbosi@yahoo.com Or Prof Brian Eley, Department Of Paediatrics And Child 
Health, Red Cross Children’s Hospital, Klipfontein Road, 5th Floor, ICH Building, 
Rondebosch, 7700, Telephone: 083-9477637; Email: brian.eley@uct.ac.za 
This research has been approved by the Ethics Committee of the University of Cape Town 
and the HREC Convener can be reached at Prof Mark Blockman, E53, Ground Floor, Old 
Main Building, Groote Schuur Hospital, Observatory, Cape Town. 
PLEASE KEEP A COPY OF THE SIGNED INFORMED ASSENT 
ASSENT: 
Statement of child giving consent: 
I have had this study explained to me in detail in a manner I understand. I understand that my 
participation is voluntary. The risks and benefits of the research study to judge that I want to 
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take part in it have been explained to me. I understand that I may freely stop being part of 
this study at any time. I have received a copy of this assent form and additional information 
sheet to keep for myself. 
I agree to take part in the study. 
NAME: __________________________________ 
SIGNATURE: ______________________________ 




DATE: ____________________________________    
Statement of person obtaining informed assent: 
I have fully explained this research to ________________________________________.  
I have given sufficient information, including risks and benefits to make an informed 






ETHICS APPROVAL, HUMAN RESEARCH ETHICS COMMITTEE, FACULTY 
OF HEALTH SCIENCES, UNIVERSITY OF CAPE TOWN 
Signature removed to avoid exposure online
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STUDY APPROVAL, RED CROSS WAR MEMORIAL CHILDREN’S HOSPITAL, 
CAPE TOWN 
Signature removed to avoid exposure online
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INSTRUCTIONS TO AUTHORS – PLOS ONE 
Submission Guidelines 
Related information for authors 
• Submission system
• Journal scope and publication criteria
• Getting started guide
• Guidelines for revisions
• Publication fees
Style and Format 
File format Manuscript files can be in the following formats: DOC, DOCX, or RTF. 
Microsoft Word documents should not be locked or protected.  
LaTeX manuscripts must be submitted as PDFs. Read the LaTeX 
guidelines. 
Length Manuscripts can be any length. There are no restrictions on word count, 
number of figures, or amount of supporting information.  
We encourage you to present and discuss your findings concisely. 
Font Use a standard font size and any standard font, except for the font named 
“Symbol”. To add symbols to the manuscript, use the Insert → Symbol 




Headings Limit manuscript sections and sub-sections to 3 heading levels. Make 
sure heading levels are clearly indicated in the manuscript text. 
Layout and 
spacing 
Manuscript text should be double-spaced. 
Do not format text in multiple columns. 
Page and line 
numbers 
Include page numbers and line numbers in the manuscript file. Use 
continuous line numbers (do not restart the numbering on each page). 
Footnotes Footnotes are not permitted. If your manuscript contains footnotes, move 
the information into the main text or the reference list, depending on the 
content. 
Language Manuscripts must be submitted in English.  
You may submit translations of the manuscript or abstract as supporting 
information. Read the supporting information guidelines. 
Abbreviations Define abbreviations upon first appearance in the text. 
Do not use non-standard abbreviations unless they appear at least three 
times in the text. 
Keep abbreviations to a minimum. 
Reference style PLOS uses “Vancouver” style, as outlined in the ICMJE sample 
references. 
See reference formatting examples and additional instructions below. 
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Equations We recommend using MathType for display and inline equations, as it 
will provide the most reliable outcome. If this is not possible, Equation 
Editor or Microsoft's Insert→Equation function is acceptable. 
Avoid using MathType, Equation Editor, or the Insert→Equation function 
to insert single variables (e.g., “a² + b² = c²”), Greek or other 
symbols (e.g., β, Δ, or ′ [prime]), or mathematical operators (e.g., x, ≥, 
or  ±) in running text. Wherever possible, insert single symbols as normal 
text with the correct Unicode (hex) values. 
Do not use MathType, Equation Editor, or the Insert→Equation function 
for only a portion of an equation. Rather, ensure that the entire equation is 
included. Equations should not contain a mix of different equation tools. 
Avoid “hybrid” inline or display equations, in which part is text and part 
is MathType, or part is MathType and part is Equation Editor. 
Nomenclature  Use correct and established nomenclature wherever possible. 
Units of 
measurement 
Use SI units. If you do not use these exclusively, 
provide the SI value in parentheses after each 
value. Read more about SI units. 
Drugs 
Provide the Recommended International Non-
Proprietary Name (rINN). 
Species names 
Write in italics (e.g., Homo sapiens). Write out in full 
the genus and species, both in the title of the manuscript 
and at the first mention of an organism in a paper. After 
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first mention, the first letter of the genus name followed 





Write in italics. Use the recommended name by 
consulting the appropriate genetic nomenclature 
database (e.g., HGNC for human genes; we strongly 
recommend using this tool to check against previously 
approved names). It is sometimes advisable to indicate 
the synonyms for the gene the first time it appears in the 
text. Gene prefixes such as those used for oncogenes or 
cellular localization should be shown in roman typeface 
(e.g., v-fes, c-MYC). 
Allergens 
The systematic allergen nomenclature of the World 
Health Organization/International Union of 
Immunological Societies (WHO/IUIS) Allergen 
Nomenclature Sub-committee should be used for 
manuscripts that include the description or use of 
allergenic proteins. For manuscripts describing new 
allergens, the systematic name of the allergen should be 
approved by the WHO/IUIS Allergen Nomenclature 
Sub-Committee prior to manuscript publication. 
Examples of the systematic allergen nomenclature can 
be found at the WHO/IUIS Allergen Nomenclature site. 
 
Copyediting manuscripts  
 
Prior to submission, authors who believe their manuscripts would benefit from professional 
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editing are encouraged to use language-editing and copyediting services. Obtaining this 
service is the responsibility of the author, and should be done before initial submission. 
These services can be found on the web using search terms like “scientific editing 
service” or “manuscript editing service.”  
 
Submissions are not copyedited before publication.  
 
Submissions that do not meet the  PLOS ONE publication criterion for language 
standards may be rejected.  
Manuscript Organization 




The following elements are required, in order: 






The following elements can be renamed as needed and presented in any 
order: 





• Conclusions (optional) 
Ending 
section 
The following elements are required, in order: 
• Acknowledgments 
• References 
• Supporting information captions (if applicable) 
Other 
elements 
• Figure captions are inserted immediately after the first paragraph in 
which the figure is cited. Figure files are uploaded separately. 
• Tables are inserted immediately after the first paragraph in which 
they are cited. 
• Supporting information files are uploaded separately. 
  
  Please refer to our downloadable sample files to ensure that your submission meets 
our formatting requirements: 
• Download sample title, author list, and affiliations page (PDF) 
• Download sample manuscript body (PDF) 
Viewing Figures and Supporting Information in the compiled submission PDF  
The compiled submission PDF includes low-resolution preview images of the figures after 
the reference list. The function of these previews is to allow you to download the entire 
submission as quickly as possible. Click the link at the top of each preview page to 
download a high-resolution version of each figure. Links to download Supporting 
Information files are also available after the reference list.  
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Parts of a Submission 
Title 
Include a full title and a short title for the manuscript. 






concise, and comprehensible 
to readers outside the field 
Impact of cigarette smoke exposure on 
innate immunity: A Caenorhabditis 
elegans model 
Solar drinking water disinfection 
(SODIS) to reduce childhood diarrhoea 






State the topic of the study Cigarette smoke exposure and innate 
immunity 
SODIS and childhood diarrhoea 
Titles should be written in sentence case (only the first word of the text, proper nouns, and 
genus names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, 
systematic reviews, or meta-analyses, the subtitle should include the study design. 
Author list 
Authorship requirements  
 
All authors must meet the criteria for authorship as outlined in the  authorship policy. Those 
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who contributed to the work but do not meet the criteria for authorship can be mentioned in 
the Acknowledgments.  Read more about Acknowledgments.  
The corresponding author must provide an ORCID iD at the time of submission by entering 
it in the user profile in the submission system.  Read more about ORCID.  
Author names and affiliations 
Enter author names on the title page of the manuscript and in the online submission system. 
On the title page, write author names in the following order: 
• First name (or initials, if used)
• Middle name (or initials, if used)
• Last name (surname, family name)
Each author on the list must have an affiliation. The affiliation includes department, 
university, or organizational affiliation and its location, including city, state/province (if 
applicable), and country. Authors have the option to include a current address in addition to 
the address of their affiliation at the time of the study. The current address should be listed 
in the byline and clearly labeled “current address.” At a minimum, the address must include 
the author’s current institution, city, and country. 
If an author has multiple affiliations, enter all affiliations on the title page only. In the 
submission system, enter only the preferred or primary affiliation. Author affiliations will 
be listed in the typeset PDF article in the same order that authors are listed in the 
submission. 
Author names will be published exactly as they appear in the manuscript file. Please 




The submitting author is automatically designated as the corresponding author in the 
submission system. The corresponding author is the primary contact for the journal office 
and the only author able to view or change the manuscript while it is under editorial 
consideration. 
The corresponding author role may be transferred to another coauthor. However, note that 
transferring the corresponding author role also transfers access to the manuscript. (To 
designate a new corresponding author while the manuscript is still under consideration, 
watch the video tutorial below.) 
Only one corresponding author can be designated in the submission system, but this does 
not restrict the number of corresponding authors that may be listed on the article in the 
event of publication. Whoever is designated as a corresponding author on the title page of 
the manuscript file will be listed as such upon publication. Include an email address for 
each corresponding author listed on the title page of the manuscript. 
  How to select a new corresponding author in Editorial Manager 
 
 
Consortia and group authorship 
If a manuscript is submitted on behalf of a consortium or group, include its name in the 
manuscript byline. Do not add it to the author list in the submission system. You may 




PubMed only indexes individual consortium or group author members listed in the article 
byline. If included, these individuals must qualify for authorship according to our criteria. 
Read the group authorship policy.  
Author contributions 
Provide at minimum one contribution for each author in the submission system. Use the 
CRediT taxonomy to describe each contribution. Read the policy and the full list of roles. 
Contributions will be published with the final article, and they should accurately reflect 
contributions to the work. The submitting author is responsible for completing this 
information at submission, and we expect that all authors will have reviewed, discussed, 
and agreed to their individual contributions ahead of this time. 
PLOS ONE will contact all authors by email at submission to ensure that they are aware of 
the submission. 
Cover letter 
Upload a cover letter as a separate file in the online system. The length limit is 1 page. 
The cover letter should include the following information: 
• Summarize the study’s contribution to the scientific literature 
• Relate the study to previously published work 
• Specify the type of article (for example, research article, systematic review, meta-
analysis, clinical trial) 
• Describe any prior interactions with PLOS regarding the submitted manuscript 
• Suggest appropriate Academic Editors to handle your manuscript (see the full list of 
Academic Editors)  
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• List any opposed reviewers 
IMPORTANT: Do not include requests to reduce or waive publication fees in the cover 
letter. This information will be entered separately in the online submission system. 
Read about publication fee assistance.  
Title page 
The title, authors, and affiliations should all be included on a title page as the first page of 
the manuscript file.   
   Download our sample title, author list, and affiliations page (PDF)  
Abstract 
The Abstract comes after the title page in the manuscript file. The abstract text is also 
entered in a separate field in the submission system.   
The Abstract should: 
• Describe the main objective(s) of the study 
• Explain how the study was done, including any model organisms used, without 
methodological detail 
• Summarize the most important results and their significance 
• Not exceed 300 words 
Abstracts should not include: 
• Citations 




The introduction should: 
• Provide background that puts the manuscript into context and allows readers outside 
the field to understand the purpose and significance of the study 
• Define the problem addressed and why it is important 
• Include a brief review of the key literature 
• Note any relevant controversies or disagreements in the field 
• Conclude with a brief statement of the overall aim of the work and a comment about 
whether that aim was achieved 
Materials and Methods 
The Materials and Methods section should provide enough detail to allow suitably skilled 
investigators to fully replicate your study. Specific information and/or protocols for new 
methods should be included in detail. If materials, methods, and protocols are well 
established, authors may cite articles where those protocols are described in detail, but the 
submission should include sufficient information to be understood independent of these 
references. 
Protocol documents for clinical trials, observational studies, and other non-laboratory 
investigations may be uploaded as supporting information. We recommend depositing 
laboratory protocols at protocols.io. Read detailed instructions for depositing and sharing 
your laboratory protocols. 
Human or animal subjects and/or tissue or field sampling 
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Methods sections describing research using human or animal subjects and/or tissue or field 
sampling must include required ethics statements. For details, consult the reporting 
guidelines for specific study types. 
Data 
PLOS journals require authors to make all data underlying the findings described in their 
manuscript fully available without restriction, with rare exception. 
Large data sets, including raw data, may be deposited in an appropriate public 
repository. See our list of recommended repositories. 
For smaller data sets and certain data types, authors may provide their data 
within supporting information files accompanying the manuscript. Authors should take care 
to maximize the accessibility and reusability of the data by selecting a file format from 
which data can be efficiently extracted (for example, spreadsheets or flat files should be 
provided rather than PDFs when providing tabulated data). 
For more information on how best to provide data, read our policy on data availability. 
PLOS does not accept references to “data not shown.” 
Cell lines 
Methods sections describing research using cell lines must state the origin of the cell lines 
used. See the reporting guidelines for cell line research. 
Laboratory protocols 
To enhance the reproducibility of your results, we recommend and encourage you to 
deposit laboratory protocols in protocols.io, where protocols can be assigned their own 
persistent digital object identifiers (DOIs). 
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To include a link to a protocol in your article: 
1. Describe your step-by-step protocol on protocols.io 
2. Select Get DOI to issue your protocol a persistent digital object identifier (DOI)  
3. Include the DOI link in the Methods section of your manuscript using the following 
format provided by protocols.io: 
http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI] 
At this stage, your protocol is only visible to those with the link. This allows editors and 
reviewers to consult your protocol when evaluating the manuscript. You can make your 
protocols public at any time by selecting Publish on the protocols.io site. Any referenced 
protocol(s) will automatically be made public when your article is published. 
New taxon names 
Methods sections of manuscripts adding new zoological, botanical, or fungal taxon names 
to the literature must follow the guidelines for new taxon names. 
Results, Discussion, Conclusions 
These sections may all be separate, or may be combined to create a mixed 
Results/Discussion section (commonly labeled “Results and Discussion”) or a mixed 
Discussion/Conclusions section (commonly labeled “Discussion”). These sections may be 
further divided into subsections, each with a concise subheading, as appropriate. These 
sections have no word limit, but the language should be clear and concise. 
Together, these sections should describe the results of the experiments, the interpretation of 
these results, and the conclusions that can be drawn. 
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Authors should explain how the results relate to the hypothesis presented as the basis of the 
study and provide a succinct explanation of the implications of the findings, particularly in 
relation to previous related studies and potential future directions for research. 
PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors 
should avoid overstating their conclusions. See the PLOS ONE Criteria for Publication for 
more information. 
Acknowledgments 
Those who contributed to the work but do not meet our authorship criteria should be listed 
in the Acknowledgments with a description of the contribution. 
Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to 
be named. 
PLOS journals publicly acknowledge the indispensable efforts of our editors and reviewers 
on an annual basis. To ensure equitable recognition and avoid any appearance of partiality, 
do not include editors or peer reviewers—named or unnamed—in the Acknowledgments.  
 
Do not include funding sources in the Acknowledgments or anywhere else in the 
manuscript file. Funding information should only be entered in the financial disclosure 
section of the submission system.  
References 
Any and all available works can be cited in the reference list. Acceptable sources include: 
• Published or accepted manuscripts 




Do not cite the following sources in the reference list: 
• Unavailable and unpublished work, including manuscripts that have been submitted 
but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include 
those data as supplementary material or deposit the data in a publicly available 
database. 
• Personal communications (these should be supported by a letter from the relevant 
authors but not included in the reference list) 
References are listed at the end of the manuscript and numbered in the order that they 
appear in the text. In the text, cite the reference number in square brackets (e.g., “We used 
the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the 
numbered citation (citation-sequence) method and first six authors, et al. 
Do not include citations in abstracts.  
Make sure the parts of the manuscript are in the correct order before ordering the citations. 
Formatting references 
Because all references will be linked electronically as much as possible to the papers they 
cite, proper formatting of the references is crucial.   
PLOS uses the reference style outlined by the International Committee of Medical Journal 
Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed 
below. Additional examples are in the ICMJE sample references. 
A reference management tool, EndNote, offers a current style file that can assist you with 
the formatting of your references. If you have problems with any reference management 
program, please contact the source company's technical support.  
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Journal name abbreviations should be those found in the National Center for Biotechnology 
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Note: A DOI number for the full-text article is acceptable as an 
alternative to or in addition to traditional volume and page 
numbers. When providing a DOI, adhere to the format in the example 
above with both the label and full DOI included at the end of the 
reference (doi: 10.1016/j.molimm.2014.11.005). Do not provide a 
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Dec 14; revised 2016 Dec 15; cited 2017 Feb 9]: [12 p.]. Available from: 
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Fountain H. For Already Vulnerable Penguins, Study Finds Climate 
Change Is Another Danger. The New York Times. 2014 Jan 29 [Cited 





Allen L. Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. 




sites, or other 
written works) 





Wells A. Exploring the development of the independent, electronic, 
scholarly journal. M.Sc. Thesis, The University of Sheffield. 1999. 
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or TV shows) 
Hitchcock A, producer and director. Rear Window [Film]; 1954. Los 
Angeles: MGM. 
Supporting information 
Authors can submit essential supporting files and multimedia files along with their 
manuscripts. All supporting information will be subject to peer review. All file types can be 
submitted, but files must be smaller than 20 MB in size. 
Authors may use almost any description as the item name for a supporting information file 
as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 
Appendix,” “S1 Table” and “S2 Table,” and so forth.   
Supporting information files are published exactly as provided, and are not copyedited. 
Supporting information captions 
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List supporting information captions at the end of the manuscript file. Do not submit 
captions in a separate file. 
The file number and name are required in a caption, and we highly recommend including a 
one-line title as well. You may also include a legend in your caption, but it is not required. 
Example caption 
 
S1 Text. Title is strongly recommended. Legend is optional.  
In-text citations 
We recommend that you cite supporting information in the manuscript text, but this is not a 
requirement. If you cite supporting information in the text, citations do not need to be in 
numerical order. 
Read the supporting information guidelines for more details about submitting supporting 
information and multimedia files.  
Figures and tables 
Figures 
Do not include figures in the main manuscript file. Each figure must be prepared and 
submitted as an individual file. 
Cite figures in ascending numeric order at first appearance in the manuscript file. 




Figure captions must be inserted in the text of the manuscript, immediately following the 
paragraph in which the figure is first cited (read order). Do not include captions as part of 
the figure files themselves or submit them in a separate document. 
At a minimum, include the following in your figure captions: 
• A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, 
Fig 2, Fig 3, etc). Match the label of your figure with the name of the file uploaded 
at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named 
“Fig1.tif”). 
• A concise, descriptive title 
The caption may also include a legend as needed. 
Read more about figure captions.  
Tables 
Cite tables in ascending numeric order upon first appearance in the manuscript file. 
Place each table in your manuscript file directly after the paragraph in which it is first cited 
(read order). Do not submit your tables in separate files. 
Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the 
table. Place legends, footnotes, and other text below the table.  
Read the guidelines for tables.  
Statistical reporting 
Manuscripts submitted to PLOS ONE are expected to report statistical methods in sufficient 
detail for others to replicate the analysis performed. Ensure that results are rigorously 
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reported in accordance with community standards and that the statistical methods employed 
are appropriate for the study design. 
Consult the following resources for additional guidance: 
• SAMPL guidelines, for general guidance on statistical reporting 
• PLOS ONE guidelines, for clinical trials requirements 
• PLOS ONE guidelines, for systematic review and meta-analysis requirements 
• EQUATOR, for specific reporting guidelines for a range of other study types 
Reporting of statistical methods 
In the methods, include a section on statistical analysis that reports a detailed description of 
the statistical methods. In this section: 
• List the name and version of any software package used, alongside any relevant 
references 
• Describe the technical details or procedures required to reproduce the analysis 
• Provide the repository identifier for any code used in the analysis (See our code-
sharing policy.) 
Statistical reporting guidelines: 
• Identify research design and independent variables as being between- or within-
subjects 
• For pre-processed data:  
o Describe any analysis carried out to confirm the data meets the assumptions 




o If data were transformed include this information, with a reason for doing so 
and a description of the transformation performed 
• Provide details of how outliers were treated and your analysis, both with the full 
dataset and with the outliers removed 
• If relevant, describe how missing/excluded data were handled 
• Define the threshold for significance (alpha) 
• If appropriate, provide sample sizes, along with a description of how they were 
determined. If a sample size calculation was performed, specify the inputs for 
power, effect size and alpha. Where relevant, report the number of independent 
replications for each experiment. 
• For analyses of variance (ANOVAs), detail any post hoc tests that were performed 
• Include details of any corrections applied to account for multiple comparisons. If 
corrections were not applied, include a justification for not doing so 
• Describe all options for statistical procedures. For example, if t-tests were 
performed, state whether these were one- or two-tailed. Include details of the type 
of t-test conducted (e.g. one sample, within-/between-subjects). 
• For step-wise multiple regression analyses:  
o Report the alpha level used 
o Discuss whether the variables were assessed for collinearity and interaction 
o Describe the variable selection process by which the final model was 
developed (e.g., forward-stepwise; best subset). See SAMPL guidelines. 
• For Bayesian analysis explain the choice of prior trial probabilities and how they 
were selected. Markov chain Monte Carlo settings should be reported. 
Reporting of statistical results 




• Units of measurement. Clearly define measurement units in all tables and figures. 
• Properties of distribution. It should be clear from the text which measures of 
variance (standard deviation, standard error of the mean, confidence intervals) and 
central tendency (mean, median) are being presented. 
• Regression analyses. Include the full results of any regression analysis performed 
as a supplementary file. Include all estimated regression coefficients, their standard 
error, p-values, and confidence intervals, as well as the measures of goodness of fit. 
• Reporting parameters. Test statistics (F/t/r) and associated degrees of freedom 
should be provided. Effect sizes and confidence intervals should be reported where 
appropriate. If percentages are provided, the numerator and denominator should also 
be given. 
• P-values. Report exact p-values for all values greater than or equal to 0.001. P-
values less than 0.001 may be expressed as p < 0.001, or as exponentials in studies 
of genetic associations. 
• Displaying data in plots. Format plots so that they accurately depict the sample 
distribution. 3D effects in plots can bias and hinder interpretation of values, so 
avoid them in cases where regular plots are sufficient to display the data. 
• Open data. As explained in PLOS’s Data Policy, be sure to make individual data 
points, underlying graphs and summary statistics available at the time of 
publication. Data can be deposited in a repository or included within the Supporting 
Information files. 
Data reporting 
All data and related metadata underlying the findings reported in a submitted manuscript 
should be deposited in an appropriate public repository, unless already provided as part of 
the submitted article. 
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See instructions on providing underlying data to support blot and gel results 
Read our policy on data availability.  
Repositories may be either subject-specific (where these exist) and accept specific types of 
structured data, or generalist repositories that accept multiple data types. We recommend 
that authors select repositories appropriate to their field. Repositories may be subject-
specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as 
long as DOIs or accession numbers are provided and the data are at least as open as CC 
BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy 
digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of 
Approval. Large, international databases are more likely to persist than small, local ones. 
See our list of recommended repositories.  
To support data sharing and author compliance of the PLOS data policy, we have integrated 
our submission process with a select set of data repositories. The list is neither 
representative nor exhaustive of the suitable repositories available to authors. Current 
repository integration partners include Dryad and FlowRepository. Please contact 
data@plos.org to make recommendations for further partnerships. 
Instructions for PLOS submissions with data deposited in an integration partner repository: 
• Deposit data in the integrated repository of choice. 
• Once deposition is final and complete, the repository will provide you with a dataset 
DOI (provisional) and private URL for reviewers to gain access to the data. 
• Enter the given data DOI into the full Data Availability Statement, which is 
requested in the Additional Information section of the PLOS submission form. Then 
provide the URL passcode in the Attach Files section. 
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If you have any questions, please email us. 
Accession numbers 
All appropriate data sets, images, and information should be deposited in an appropriate 
public repository. See our list of recommended repositories. 
Accession numbers (and version numbers, if appropriate) should be provided in the Data 
Availability Statement. Accession numbers or a citation to the DOI should also be provided 
when the data set is mentioned within the manuscript. 
In some cases authors may not be able to obtain accession numbers of DOIs until the 
manuscript is accepted; in these cases, the authors must provide these numbers at 
acceptance. In all other cases, these numbers must be provided at full submission. 
Identifiers 
As much as possible, please provide accession numbers or identifiers for all entities such as 
genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for 
example: 
• Ensembl 
• Entrez Gene 
• FlyBase 
• InterPro 
• Mouse Genome Database (MGD) 
• Online Mendelian Inheritance in Man (OMIM) 
• PubChem 




You can choose to upload a “Striking Image” that we may use to represent your article 
online in places like the journal homepage or in search results. 
The striking image must be derived from a figure or supporting information file from the 
submission, i.e., a cropped portion of an image or the entire image. Striking images should 
ideally be high resolution, eye-catching, single panel images, and should ideally avoid 
containing added details such as text, scale bars, and arrows. 
If no striking image is uploaded, we will designate a figure from the submission as the 
striking image. 
Striking images should not contain potentially identifying images of people.  Read our 
policy on identifying information.  
 
The PLOS licenses and copyright policy also applies to striking images.  
Additional Information Requested at Submission 
Financial Disclosure Statement 
This information should describe sources of funding that have supported the work. It is 
important to gather these details prior to submission because your financial disclosure 
statement cannot be changed after initial submission without journal approval. If your 
manuscript is published, your statement will appear in the Funding section of the article. 
Enter this statement in the Financial Disclosure section of the submission form. Do not 
include it in your manuscript file. 
The statement should include: 
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• Specific grant numbers 
• Initials of authors who received each award 
• Full names of commercial companies that funded the study or authors 
• Initials of authors who received salary or other funding from commercial companies 
• URLs to sponsors’ websites 
Also state whether any sponsors or funders (other than the named authors) played any role 
in: 
• Study design 
• Data collection and analysis 
• Decision to publish 
• Preparation of the manuscript 
If they had no role in the research, include this sentence: “The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the manuscript.” 
If the study was unfunded, include this sentence as the Financial Disclosure statement: 
“The author(s) received no specific funding for this work." 
Read our policy on disclosure of funding sources.  
Competing interests 
This information should not be in your manuscript file; you will provide it via our 
submission system. 
All potential competing interests must be declared in full. If the submission is related to 
any patents, patent applications, or products in development or for market, these details, 
including patent numbers and titles, must be disclosed in full. 
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Read our policy on competing interests.  
Manuscripts disputing published work 
For manuscripts disputing previously published work, it is PLOS ONE policy to invite a 
signed review by the disputed author during the peer review process. This procedure is 
aimed at ensuring a thorough, transparent, and productive review process. 
If the disputed author chooses to submit a review, it must be returned in a timely fashion 
and contain a full declaration of all competing interests. The Academic Editor will consider 
any such reviews in light of the competing interest. 
Authors submitting manuscripts disputing previous work should explain the relationship 
between the manuscripts in their cover letter, and will be required to confirm that they 
accept the conditions of this review policy before the manuscript is considered further. 
Related manuscripts 
Upon submission, authors must confirm that the manuscript, or any related manuscript, is 
not currently under consideration or accepted elsewhere. If related work has been submitted 
to PLOS ONE or elsewhere, authors must include a copy with the submitted article. 
Reviewers will be asked to comment on the overlap between related submissions. 
We strongly discourage the unnecessary division of related work into separate manuscripts, 
and we will not consider manuscripts that are divided into “parts.” Each submission 
to PLOS ONE must be written as an independent unit and should not rely on any work that 
has not already been accepted for publication. If related manuscripts are submitted to PLOS 
ONE, the authors may be advised to combine them into a single manuscript at the editor's 
discretion. 




PLOS encourages authors to post preprints as a way to accelerate the dissemination of 
research and supports authors who wish to share their work early and receive feedback 
before formal peer review. Deposition of manuscripts with preprint servers does not impact 
consideration of the manuscript at any PLOS journal. 
Authors posting on bioRxiv or medRxiv may submit directly to relevant PLOS journals 
through the direct transfer to journal service. 
Authors submitting manuscripts in the life sciences to PLOS ONE may opt-in to post their 
work on bioRxiv during the PLOS ONE initial submission process. 
Read more about preprints.  
 
Learn how to post a preprint to bioRxiv during PLOS ONE initial submission.  
Guidelines for Specific Study Types 
Registered Reports 
Submission and format requirements for Registered Report Protocols and Registered 
Reports are similar to those for a regular submission and may be specific to your study 
type. For instance, if your Registered Report Protocol submission is about a Clinical Trial 
or a Systematic Review, follow the appropriate guidelines. 
For Registered Report Protocols: 
• Provide enough methodological detail to make the study reproducible and replicable 
• Confirm that data will be made available upon study completion in keeping with the 
PLOS Data policy 
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• Include ethical approval or waivers, if applicable 
• Preliminary or pilot data may be included, but only if necessary to support the 
feasibility of the study or as a proof of principle  
• For meta-analyses or a Clinical Trials, consider using the protocol-specific reporting 
guidelines PRISMA-P or SPIRIT respectively 
For more guidance on format and presentation of a protocol, consult the sample template 
hosted by the Open Science Framework. Discipline-specific and study-specific templates 
are also available. 
If data need to be collected, modified or processed specifically for your study, or if 
participants need to be recruited specifically for your study, then it should occur only after 
your Registered Report Protocol is accepted for publication.  
 
For Registered Report Research Articles: 
• Report the results of all planned analyses and, if relevant, detail and justify all 
deviations from the protocol.  
• The manuscript may also contain exploratory, unplanned analyses. 
Read more about Registered Report framework. 
Human subjects research 
All research involving human participants must have been approved by the 
authors’ Institutional Review Board (IRB) or by equivalent ethics committee(s), and must 
have been conducted according to the principles expressed in the Declaration of Helsinki. 
Authors should be able to submit, upon request, a statement from the IRB or ethics 
committee indicating approval of the research. We reserve the right to reject work that we 
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believe has not been conducted to a high ethical standard, even when formal approval has 
been obtained.  
 
Subjects must have been properly instructed and have indicated that they consent to 
participate by signing the appropriate informed consent paperwork. Authors may be asked 
to submit a blank, sample copy of a subject consent form. If consent was verbal instead of 
written, or if consent could not be obtained, the authors must explain the reason in the 
manuscript, and the use of verbal consent or the lack of consent must have been approved 
by the IRB or ethics committee.  
 
All efforts should be made to protect patient privacy and anonymity. Identifying 
information, including photos, should not be included in the manuscript unless the 
information is crucial and the individual has provided written consent by completing 
the  Consent Form for Publication in a PLOS Journal (PDF). Download additional 
translations of the form from the Downloads and Translations page. More information 
about patient privacy, anonymity, and informed consent can be found in the International 
Committee of Medical Journal Editors (ICMJE) Privacy and Confidentiality guidelines.  
Manuscripts should conform to the following reporting guidelines: 
• Studies of diagnostic accuracy: STARD  
• Observational studies: STROBE  
• Microarray experiments: MIAME  
• Other types of health-related research: Consult the EQUATOR web site for 
appropriate reporting guidelines 
Methods sections of papers on research using human subjects or samples must include 
ethics statements that specify: 
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• The name of the approving institutional review board or equivalent 
committee(s). If approval was not obtained, the authors must provide a detailed 
statement explaining why it was not needed 
• Whether informed consent was written or oral. If informed consent was oral, it 
must be stated in the manuscript:  
o Why written consent could not be obtained 
o That the Institutional Review Board (IRB) approved use of oral consent 
o How oral consent was documented 
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, 
religion, sex/gender, sexual orientation, or other socially constructed groupings, authors 
should: 
• Explicitly describe their methods of categorizing human populations 
• Define categories in as much detail as the study protocol allows 
• Justify their choices of definitions and categories, including for example whether 
any rules of human categorization were required by their funding agency 
• Explain whether (and if so, how) they controlled for confounding variables such as 
socioeconomic status, nutrition, environmental exposures, or similar factors in their 
analysis 
In addition, outmoded terms and potentially stigmatizing labels should be changed to more 
current, acceptable terminology. Examples: “Caucasian” should be changed to “white” or 
“of [Western] European descent” (as appropriate); “cancer victims” should be changed to 
“patients with cancer.” 
For papers that include identifying, or potentially identifying, information, authors must 
download the Consent Form for Publication in a PLOS Journal, which the individual, 
parent, or guardian must sign once they have read the paper and been informed about the 
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terms of PLOS open-access license. The signed consent form should not be submitted with 
the manuscript, but authors should securely file it in the individual's case notes and the 
methods section of the manuscript should explicitly state that consent authorization for 
publication is on file, using wording like: 
The individual in this manuscript has given written informed consent (as outlined in 
PLOS consent form) to publish these case details. 
For more information about PLOS ONE policies regarding human subjects research, see 
the Publication Criteria and Editorial Policies. 
Clinical trials 
Clinical trials are subject to all policies regarding human research. PLOS ONE follows 
the World Health Organization's (WHO) definition of a clinical trial: 
A clinical trial is any research study that prospectively assigns human participants or 
groups of humans to one or more health-related interventions to evaluate the effects on 
health outcomes [...] Interventions include but are not restricted to drugs, cells and other 
biological products, surgical procedures, radiologic procedures, devices, behavioural 
treatments, process-of-care changes, preventive care, etc.  
All clinical trials must be registered in one of the publicly-accessible registries approved by 
the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must 
provide the trial registration number. Prior disclosure of results on a clinical trial registry 
site will not affect consideration for publication. We reserve the right to inform authors' 




PLOS ONE supports prospective trial registration (i.e. before participant recruitment has 
begun) as recommended by the ICMJE's clinical trial registration policy. Where trials 
were not publicly registered before participant recruitment began, authors must: 
• Register all related clinical trials and confirm they have done so in the Methods 
section 
• Explain in the Methods the reason for failing to register before participant 
recruitment 
Clinical trials must be reported according to the relevant reporting guidelines, 
i.e. CONSORT for randomized controlled trials, TREND for non-randomized trials, 
and other specialized guidelines as appropriate. The intervention should be described 
according to the requirements of the TIDieR checklist and guide. Submissions must also 
include the study protocol as supporting information, which will be published with the 
manuscript if accepted. 
Authors of manuscripts describing the results of clinical trials must adhere to 
the CONSORT reporting guidelines appropriate to their trial design, available on 
the CONSORT Statement web site. Before the paper can enter peer review, authors must: 
• Provide the registry name and number in the methods section of the manuscript 
• Provide a copy of the trial protocol as approved by the ethics committee and a 
completed CONSORT checklist as supporting information (which will be published 
alongside the paper, if accepted). This should be named S1 CONSORT Checklist. 
• Include the CONSORT flow diagram as the manuscript's “Fig 1” 
Any deviation from the trial protocol must be explained in the paper. Authors must 
explicitly discuss informed consent in their paper, and we reserve the right to ask for a copy 
of the patient consent form. 
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The methods section must include the name of the registry, the registry number, and the 
URL of your trial in the registry database for each location in which the trial is registered. 
Animal research 
All research involving vertebrates or cephalopods must have approval from the authors' 
Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee(s), 
and must have been conducted according to applicable national and international 
guidelines. Approval must be received prior to beginning research. 
Manuscripts reporting animal research must state in the Methods section: 
• The full name of the relevant ethics committee that approved the work, and the 
associated permit number(s). 
• Where ethical approval is not required, the manuscript should include a clear 
statement of this and the reason why. Provide any relevant regulations under which 
the study is exempt from the requirement for approval. 
• Relevant details of steps taken to ameliorate animal suffering. 
Example ethics statement  
 
This study was carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol 
was approved by the Committee on the Ethics of Animal Experiments of the University of 
Minnesota (Protocol Number: 27-2956). All surgery was performed under sodium 
pentobarbital anesthesia, and all efforts were made to minimize suffering. 
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Authors should always state the organism(s) studied in the Abstract. Where the study may 
be confused as pertaining to clinical research, authors should also state the animal model in 
the title. 
To maximize reproducibility and potential for re-use of data, we encourage authors to 
follow the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for 
all submissions describing laboratory-based animal research and to upload a completed 
ARRIVE Guidelines Checklist to be published as supporting information. 
Non-human primates 
Manuscripts describing research involving non-human primates must report details of 
husbandry and animal welfare in accordance with the recommendations of the Weatherall 
report, The use of non-human primates in research, including: 
• Information about housing, feeding, and environmental enrichment. 
• Steps taken to minimize suffering, including use of anesthesia and method of 
sacrifice, if appropriate. 
Random source animals 
Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the 
USA), shelter, or stray animals will be subject to additional scrutiny and may be rejected if 
sufficient ethical and scientific justification for the study design is lacking. 
Unacceptable euthanasia methods and anesthetic agents 
Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the 
American Veterinary Medical Association or use of an anesthesia method(s) that is widely 
prohibited (e.g., chloral hydrate, ether, chloroform) must include at the time of initial 
submission, scientific justification for use in the specific study design, as well as 
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confirmation of approval for specific use from their animal research ethics committee. 
These manuscripts may be subject to additional ethics considerations prior to publication. 
Humane endpoints 
Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) 
is a likely outcome or a planned experimental endpoint, must comprehensively report 
details of study design, rationale for the approach, and methodology, including 
consideration of humane endpoints. This applies to research that involves, for instance, 
assessment of survival, toxicity, longevity, terminal disease, or high rates of incidental 
mortality. 
Definition of a humane endpoint  
 
A humane endpoint is a predefined experimental endpoint at which animals are euthanized 
when they display early markers associated with death or poor prognosis of quality of life, 
or specific signs of severe suffering or distress. Humane endpoints are used as an 
alternative to allowing such conditions to continue or progress to death following the 
experimental intervention (“death as an endpoint”), or only euthanizing animals at the end 
of an experiment. Before a study begins, researchers define the practical observations or 
measurements that will be used during the study to recognize a humane endpoint, based on 
anticipated clinical, physiological, and behavioral signs. Please see the NC3Rs guidelines 
for more information. Additional discussion of humane endpoints can be found in this 
article:  Nuno H. Franco, Margarida Correia-Neves, I. Anna S. Olsson (2012) How 
“Humane” Is Your Endpoint? — Refining the Science-Driven Approach for Termination of 




Full details of humane endpoints use must be reported for a study to be reproducible and for 
the results to be accurately interpreted. 
For studies in which death of an animal is an outcome or a planned experimental endpoint, 
authors should include the following information in the Methods section of the manuscript: 
• The specific criteria (i.e. humane endpoints) used to determine when animals should 
be euthanized. 
• The duration of the experiment. 
• The numbers of animals used, euthanized, and found dead (if any); the cause of 
death for all animals. 
• How frequently animal health and behavior were monitored. 
• All animal welfare considerations taken, including efforts to minimize suffering and 
distress, use of analgesics or anaesthetics, or special housing conditions. 
If humane endpoints were not used, the manuscript should report: 
• A scientific justification for the study design, including the reasons why humane 
endpoints could not be used, and discussion of alternatives that were considered. 
• Whether the institutional animal ethics committee specifically reviewed and 
approved the anticipated mortality in the study design. 
Observational and field studies 
Methods sections for submissions reporting on any type of field study must include ethics 
statements that specify: 
• Permits and approvals obtained for the work, including the full name of the 




• Whether the land accessed is privately owned or protected 
• Whether any protected species were sampled 
• Full details of animal husbandry, experimentation, and care/welfare, where relevant 
Paleontology and archaeology research 
Manuscripts reporting paleontology and archaeology research must include descriptions of 
methods and specimens in sufficient detail to allow the work to be reproduced. Data sets 
supporting statistical and phylogenetic analyses should be provided, preferably in a format 
that allows easy re-use. Read the policy. 
Specimen numbers and complete repository information, including museum name and 
geographic location, are required for publication. Locality information should be provided 
in the manuscript as legally allowable, or a statement should be included giving details of 
the availability of such information to qualified researchers. 
If permits were required for any aspect of the work, details should be given of all permits 
that were obtained, including the full name of the issuing authority. This should be 
accompanied by the following statement: 
All necessary permits were obtained for the described study, which complied with all 
relevant regulations.  
If no permits were required, please include the following statement: 
No permits were required for the described study, which complied with all relevant 
regulations.  




• Sharing of data and materials. Any specimen that is erected as a new species, described, 
or figured must be deposited in an accessible, permanent repository (i.e., public museum or 
similar institution). If study conclusions depend on specimens that do not fit these criteria, 
the article will be rejected under PLOS ONE's data availability criterion. 
• Ethics. PLOS ONE will not publish research on specimens that were obtained without 
necessary permission or were illegally exported. 
Systematic reviews and meta-analyses 
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a 
clearly formulated question that uses explicit, systematic methods to identify, select, and 
critically appraise relevant research, and to collect and analyze data from the studies that 
are included in the review. These reviews differ substantially from narrative-based reviews 
or synthesis articles. Statistical methods (meta-analysis) may or may not be used to analyze 
and summarize the results of the included studies. 
Reports of systematic reviews and meta-analyses must include a completed PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow 
diagram to accompany the main text. Blank templates are available here: 
• Checklist: PDF or Word document  
• Flow diagram: PDF or Word document  
Authors must also state in their “Methods” section whether a protocol exists for their 
systematic review, and if so, provide a copy of the protocol as supporting information and 
provide the registry number in the abstract. 
If your article is a systematic review or a meta-analysis you should: 
• State this in your cover letter 
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• Select “Research Article” as your article type when submitting 
• Include the PRISMA flow diagram as Fig 1 (required where applicable) 
• Include the PRISMA checklist as supporting information 
Meta-analysis of genetic association studies 
Manuscripts reporting a meta-analysis of genetic association studies must report results of 
value to the field and should be reported according to the guidelines presented in Systematic 
Reviews of Genetic Association Studies by Sagoo et al. 
On submission, authors will be asked to justify the rationale for the meta-analysis and how 
it contributes to the base of scientific knowledge in the light of previously published results. 
Authors will also be asked to complete a checklist (DOCX) outlining information about the 
justification for the study and the methodology employed. Meta-analyses that replicate 
published studies will be rejected if the authors do not provide adequate justification. 
Personal data from third-party sources 
For all studies using personal data from internet-based and other third-party sources (e.g., 
social media, blogs, other internet sources, mobile phone companies), data must be 
collected and used according to company/website Terms and Conditions, with appropriate 
permissions. All data sources must be acknowledged clearly in the Materials and Methods 
section. 
Read our policy on data availability.      
In the Ethics Statement, authors should declare any potential risks to individuals or 
individual privacy, or affirm that in their assessment, the study posed no such risks. In 
addition, the following Ethics and Data Protection requirements must be met. 
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For interventional studies, which impact participants’ experiences or data, the study 
design must have been prospectively approved by an Ethics Committee, and informed 
consent is required. The Ethics Committee may waive the requirement for approval and/or 
consent. 
For observational studies in which personal experiences and accounts are not 
manipulated, consultation with an Ethics or Data Protection Committee is recommended. 
Additional requirements apply in the following circumstances: 
• If information used could threaten personal privacy or damage the reputation of 
individuals whose data are used, an Ethics Committee should be consulted and 
informed consent obtained or specifically addressed. 
• If authors accessed any personal identifying information, an Ethics or Data 
Protection Committee should oversee data anonymization. If data were anonymized 
and/or aggregated before access and analysis, informed consent is generally not 
required. 
Note that Terms of Use contracts do not qualify as informed consent, even if they address 
the use of personal data for research.   
See our reporting guidelines for human subjects research.  
Cell lines 
Authors reporting research using cell lines should state when and where they obtained the 
cells, giving the date and the name of the researcher, cell line repository, or commercial 
source (company) who provided the cells, as appropriate. 
Authors must also include the following information for each cell line: 
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For de novo (new) cell lines, including those given to the researchers as a gift, authors 
must follow our policies for human subjects research or animal research, as appropriate. 
The ethics statement must include: 
• Details of institutional review board or ethics committee approval; AND 
• For human cells, confirmation of written informed consent from the donor, 
guardian, or next of kin 
For established cell lines, the Methods section should include: 
• A reference to the published article that first described the cell line; AND/OR 
• The cell line repository or company the cell line was obtained from, the catalogue 
number, and whether the cell line was obtained directly from the 
repository/company or from another laboratory 
Authors should check established cell lines using the ICLAC Database of Cross-
contaminated or Misidentified Cell Lines to confirm they are not misidentified or 
contaminated. Cell line authentication is recommended – e.g., by karyotyping, isozyme 
analysis, or short tandem repeats (STR) analysis – and may be required during peer review 
or after publication. 
Blots and gels 
Please review PLOS ONE’s requirements for reporting blot and gel results and providing 
the underlying raw images. 
Antibodies 




• The name of each antibody, a description of whether it is monoclonal or polyclonal, 
and the host species. 
• The commercial supplier or source laboratory. 
• The catalogue or clone number and, if known, the batch number. 
• The antigen(s) used to raise the antibody. 
• For established antibodies, a stable public identifier from the Antibody Registry. 
The manuscript should also report the following experimental details: 
• The final antibody concentration or dilution. 
• A reference to the validation study if the antibody was previously validated. If not, 
provide details of how the authors validated the antibody for the applications and 
species used.  
We encourage authors to consider adding information on new validations to a publicly 
available database such as Antibodypedia or CiteAb.  
Small and macromolecule crystal data 
Manuscripts reporting new and unpublished three-dimensional structures must include 
sufficient supporting data and detailed descriptions of the methodologies used to allow the 
reproduction and validation of the structures. All novel structures must have been deposited 
in a community endorsed database prior to submission (please see our list of recommended 
repositories). 
Small molecule single crystal data 
Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and 
inorganic molecules must deposit their data with the Cambridge Crystallographic Data 
Centre (CCDC), the Inorganic Crystal Structure Database (ICSD), or similar community 
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databases providing a recognized validation functionality. Authors are also required to 
include the relevant structure reference numbers within the main text (e.g. the CCDC ID 
number), as well as the crystallographic information files (.cif format) as Supplementary 
Information, along with the checkCIF validation reports that can be obtained via the 
International Union of Crystallography (IUCr). 
Macromolecular structures 
Authors reporting novel macromolecular structures must have deposited their data prior to 
initial submission with the Worldwide Protein Data Bank (wwPDB), the Biological 
Magnetic Resonance Data Bank (BMRB), the Electron Microscopy Data Bank (EMDB), or 
other community databases providing a recognized validation functionality. Authors must 
include the structure reference numbers within the main text and submit as Supplementary 
Information the official validation reports from these databases. 
Methods, software, databases, and tools 
PLOS ONE will consider submissions that present new methods, software, databases, or 
tools as the primary focus of the manuscript if they meet the following criteria: 
Utility  
The tool must be of use to the community and must present a proven advantage over 
existing alternatives, where applicable. Recapitulation of existing methods, software, or 
databases is not useful and will not be considered for publication. Combining data and/or 
functionalities from other sources may be acceptable, but simpler instances (i.e. presenting 
a subset of an already existing database) may not be considered. For software, databases, 
and online tools, the long-term utility should also be discussed, as relevant. This discussion 






Submissions presenting methods, software, databases, or tools must demonstrate that the 
new tool achieves its intended purpose. If similar options already exist, the submitted 
manuscript must demonstrate that the new tool is an improvement over existing options in 
some way. This requirement may be met by including a proof-of-principle experiment or 
analysis; if this is not possible, a discussion of the possible applications and some 
preliminary analysis may be sufficient.  
 
Availability  
If the manuscript’s primary purpose is the description of new software or a new software 
package, this software must be open source, deposited in an appropriate archive, and 
conform to the Open Source Definition. If the manuscript mainly describes a database, this 
database must be open-access and hosted somewhere publicly accessible, and any software 
used to generate a database should also be open source. If relevant, databases should be 
open for appropriate deposition of additional data. Dependency on commercial software 
such as Mathematica and MATLAB does not preclude a paper from consideration, 
although complete open source solutions are preferred. In these cases, authors should 
provide a direct link to the deposited software or the database hosting site from within the 
paper. If the primary focus of a manuscript is the presentation of a new tool, such as a 
newly developed or modified questionnaire or scale, it should be openly available under a 
license no more restrictive than CC BY.  
Software submissions 
Manuscripts whose primary purpose is the description of new software must provide full 
details of the algorithms designed. Describe any dependencies on commercial products or 
operating system. Include details of the supplied test data and explain how to install and run 
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the software. A brief description of enhancements made in the major releases of the 
software may also be given. Authors should provide a direct link to the deposited software 
from within the paper. 
Database submissions 
For descriptions of databases, provide details about how the data were curated, as well as 
plans for long-term database maintenance, growth, and stability. Authors should provide a 
direct link to the database hosting site from within the paper. 
Read the PLOS policy on sharing materials and software.  
New taxon names 
Zoological names 
When publishing papers that describe a new zoological taxon name, PLOS aims to comply 
with the requirements of the International Commission on Zoological Nomenclature 
(ICZN). Effective 1 January 2012, the ICZN considers an online-only publication to be 
legitimate if it meets the criteria of archiving and is registered in ZooBank, the ICZN's 
official registry. 
For proper registration of a new zoological taxon, we require two specific statements to be 
included in your manuscript. 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life 
Science Identifier (LSID), should be listed under the new species name, for example: 




You will need to contact Zoobank to obtain a GUID (LSID). Please do this as early as 
possible to avoid delay of publication upon acceptance of your manuscript. It is your 
responsibility to provide us with this information so we can include it in the final published 
paper. 
Please also insert the following text into the Methods section, in a sub-section to be called 
“Nomenclatural Acts”: 
The electronic edition of this article conforms to the requirements of the amended 
International Code of Zoological Nomenclature, and hence the new names contained herein 
are available under that Code from the electronic edition of this article. This published 
work and the nomenclatural acts it contains have been registered in ZooBank, the online 
registration system for the ICZN. The ZooBank LSIDs (Life Science Identifiers) can be 
resolved and the associated information viewed through any standard web browser by 
appending the LSID to the prefix “http://zoobank.org/”. The LSID for this publication is: 
urn:lsid:zoobank.org:pub: XXXXXXX. The electronic edition of this work was published 
in a journal with an ISSN, and has been archived and is available from the following digital 
repositories: PubMed Central, LOCKSS [author to insert any additional repositories].  
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those 
of your co-authors, has its own repository, we recommend that you also deposit the 
published online article there and include the name in your article. 
Botanical names 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with 
the requirements of the International Code of Nomenclature for algae, fungi, and plants 
(ICN). The following guidelines for publication in an online-only journal have been agreed 
such that any scientific botanical name published by us is considered effectively published 
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under the rules of the Code. Please note that these guidelines differ from those for 
zoological nomenclature, and apply only to seed plants, ferns, and lycophytes. 
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or 
English. This does not affect the requirements for scientific names, which are still to be 
Latin. 
Also effective January 2012, the electronic PDF represents a published work according to 
the ICN for algae, fungi, and plants. Therefore the new names contained in the electronic 
publication of PLOS article are effectively published under that Code from the electronic 
edition alone, so there is no longer any need to provide printed copies. 
Additional information describing recent changes to the Code can be found here. 
For proper registration of the new taxon, we require two specific statements to be included 
in your manuscript. 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life 
Science Identifier (LSID), should be listed under the new species name, for example: 
Solanum aspersum S.Knapp, sp. nov. [urn:lsid:ipni.org:names:77103633-1] Type: 
Colombia. Putumayo: vertiente oriental de la Cordillera, entre Sachamates y San Francisco 
de Sibundoy, 1600-1750 m, 30 Dec 1940, J. Cuatrecasas 11471 (holotype, COL; isotypes, 
F [F-1335119], US [US-1799731]).  
Journal staff will contact IPNI to obtain the GUID (LSID) after your manuscript is accepted 
for publication, and this information will then be added to the manuscript during the 
production phase 




The electronic version of this article in Portable Document Format (PDF) in a work with an 
ISSN or ISBN will represent a published work according to the International Code of 
Nomenclature for algae, fungi, and plants, and hence the new names contained in the 
electronic publication of a PLOS article are effectively published under that Code from the 
electronic edition alone, so there is no longer any need to provide printed copies.  
 
In addition, new names contained in this work have been submitted to IPNI, from where 
they will be made available to the Global Names Index. The IPNI LSIDs can be resolved 
and the associated information viewed through any standard web browser by appending the 
LSID contained in this publication to the prefix http://ipni.org/. The online version of this 
work is archived and available from the following digital repositories: [INSERT NAMES 
OF DIGITAL REPOSITORIES WHERE ACCEPTED MANUSCRIPT WILL BE 
SUBMITTED (PubMed Central, LOCKSS etc)].  
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those 
of your co-authors, has its own repository, we recommend that you also deposit the 
published online article there and include the name in your article. 
Fungal names 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with 
the requirements of the International Code of Nomenclature for algae, fungi, and plants 
(ICN). The following guidelines for publication in an online-only journal have been agreed 
such that any scientific botanical name published by us is considered effectively published 




Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or 
English. This does not affect the requirements for scientific names, which are still to be 
Latin. 
Also effective January 2012, the electronic PDF represents a published work according to 
the ICN for algae, fungi, and plants. Therefore the new names contained in the electronic 
publication of PLOS article are effectively published under that Code from the electronic 
edition alone, so there is no longer any need to provide printed copies. 
Additional information describing recent changes to the Code can be found here. 
For proper registration of the new taxon, we require two specific statements to be included 
in your manuscript. 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life 
Science Identifier (LSID), should be listed under the new species name, for example: 
Hymenogaster huthii. Stielow et al. 2010, sp. nov. 
[urn:lsid:indexfungorum.org:names:518624]  
You will need to contact either Mycobank or Index Fungorum to obtain the GUID (LSID). 
Please do this as early as possible to avoid delay of publication upon acceptance of your 
manuscript. It is your responsibility to provide us with this information so we can include it 
in the final published paper. Effective January 2013, all papers describing new fungal 
species must reference the identifier issued by a recognized repository in the protologue in 
order to be considered effectively published. 
In the Methods section, include a sub-section called “Nomenclature” using the following 
wording. Note that this example is for taxon names submitted to MycoBank; please 
133 
 
substitute appropriately if you have submitted to Index Fungorum using the 
prefix http://www.indexfungorum.org/Names/NamesRecord.asp?RecordID=. 
The electronic version of this article in Portable Document Format (PDF) in a work with an 
ISSN or ISBN will represent a published work according to the International Code of 
Nomenclature for algae, fungi, and plants, and hence the new names contained in the 
electronic publication of a PLOS article are effectively published under that Code from the 
electronic edition alone, so there is no longer any need to provide printed copies.  
 
In addition, new names contained in this work have been submitted to MycoBank from 
where they will be made available to the Global Names Index. The unique MycoBank 
number can be resolved and the associated information viewed through any standard web 
browser by appending the MycoBank number contained in this publication to the prefix 
http://www.mycobank.org/MB/. The online version of this work is archived and available 
from the following digital repositories: [INSERT NAMES OF DIGITAL REPOSITORIES 
WHERE ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed Central, 
LOCKSS etc)].  
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those 
of your co-authors, has its own repository, we recommend that you also deposit the 
published online article there and include the name in your article. 
Qualitative research 
Qualitative research studies use non-quantitative methods to address a defined research 
question that may not be accessible by quantitative methods, such as people's 
interpretations, experiences, and perspectives. The analysis methods are explicit, 
systematic, and reproducible, but the results do not involve numerical values or use 
statistics. Examples of qualitative data sources include, but are not limited to, interviews, 
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text documents, audio/video recordings, and free-form answers to questionnaires and 
surveys. 
Qualitative research studies should be reported in accordance to the Consolidated criteria 
for reporting qualitative research (COREQ) checklist or Standards for reporting qualitative 
research (SRQR) checklist. Further reporting guidelines can be found in the Equator 
Network's Guidelines for reporting qualitative research. 
 
